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INTRODUCTION 
     The leading causes of death in industrialized nations are lifestyle related diseases, 
caused in part by imbalanced diet, lack of exercise, poor stress management, and 
smoking.  The character of this life style is high energy intake and low energy 
consumption, which leads to a metabolic syndrome characterized by weight gain, 
dyslipidemia, insulin resistance, and hypertension.  This metabolic syndrome is the 
precursor of lifestyle related diseases. 
     Inflammation is a key component of the metabolic syndrome and has been shown to 
be involved in atherosclerosis, diabetes, cancer, and other lifestyle diseases.  Among all 
the lifestyle related diseases, cardiovascular diseases (CVD) are the number one killer of 
women and men.  One in five males and females has some form of CVD.  CVD 
accounted for 38.5 percent of all deaths or 1 of every 2.6 deaths in the United States in 
2001.  CVD mortality was about 60% of “total mortality”.  Almost 150,000 Americans 
killed by CVD each year are under 65.  In 2004 the estimated direct and indirect cost of 
CVD is $368.4 billion (9); the cost has nearly tripled in the last two yeas!   
     There are 18.2 million American; in 2002 approximately 6.3% of the population had 
diabetes, among them, 90% to 95% had type 2 diabetes.  This number is increasing by 1.3 
million per year.  The total annual economic cost of diabetes in 2002 was estimated to be 
$132 billion, or one out of every 10 health care dollars spent in the United States (8).  
Cancer is the second leading cause of death in the US, causing 1 of every 4 deaths.  
Overall costs of cancer in 2004 was $189.8 billion (6).       
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The role of inflammation in atherogenesis 
     Signs of inflammation accompany the earliest accumulation of lipid within the arterial 
wall.  The diseased endothelium begins to express adhesion molecules that selectively 
bind to circulating leukocytes.  These cell adhesion molecules include intercellular 
adhesion molecule-1 (ICAM-1).   
     Once adherent to the endothelium, inflammatory cells migrate into the subendothelial 
space, and leukocytes contribute to the local inflammatory response.  Macrophages, 
endothelial cells, and smooth muscles cells produce the pleiotropic cytokine tumor 
necrosis factor-α (TNF-α), which along with interferon-γ and interleukin-1 (IL-1) 
stimulate smooth muscle cell production of IL-6.  IL-6 is the main stimulant for the 
hepatic production of C-reactive protein (CRP) (40). 
     As the atherosclerotic lesion matures, the accumulation of foam cells leads to the 
formation of a lipid pool, rich in pro-thrombotic tissue factor.  Smooth muscle cells 
produce collagen which contributes to the strength of the fibrous cap, shielding the 
circulating blood from the pro-thrombotic lipid pool.  The synthesis and breakdown of 
collagen in the fibrous cap is dynamically mediated by inflammatory signals (49).  If pro-
inflammatory forces predominate, the fibrous cap may thin and eventually rupture, with 
release of the pro-thrombotic lipid pool into the lumen.  This may cause the acute onset 
of an ischaemic event. 
PPL and inflammation 
     Postprandial lipemia (PPL) is the sustained and elevated concentration of plasma 
triglycerides (TG) that occurs following a meal.  Americans ingest approximately 33% of 
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their daily calories from fat (3) and spend most of their day digesting a meal, placing 
them in a postprandial state for the majority of the day.  Hypertriglyceridemia leads to 
high plasma concentration of low-density lipoprotein cholesterol (LDL-C), and low 
plasma concentration of high-density lipoprotein cholesterol (HDL-C).  It has been 
shown that plasma concentration of TG, and ratios of TC/HDL-C, LDL-C/HDL-C were 
positively correlated to CRP (63, 95).  Plasma concentration of HDL-C was shown to be 
negatively correlated to CRP (27).  Studies have found that hypertriglyceridemia actived 
leukocytes, in vivo (68).  Since activation of leukocytes is obligatory for inflammation 
and atherogenesis by adhering to the endothelium via specific ligands, 
hypertiglyceridemia thus induces adhesion.  On the other hand, hypertiglyceridemia was 
found to be correlated to cell adhesion molecules, thus contributing to inflammatory 
procedure and atherosclerosis (45).  Elevated or exaggerated PPL is often observed in 
CVD patients, and is a major risk factor for CVD (71).  Based on these results, 
exaggerated PPL TG makes inflammation worse.  Omega-3 fatty acid (n-3FA) and 
aerobic exercise are two strategies that have been shown to reduce PPL. 
Fish oil reduces PPL 
     N-3FAs are long chain fatty acids (FA) that are primarily found in fish oil.  The two 
primary n-3FAs found in fish oil are eicosapentaenoic acid (EPA, 20:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3).  Researches have found n-3FA supplementation 
reduced PPL (37, 79, 85, 94).  The reduction in PPL following n-3FA supplementation is 
hypothesized to be due to either decreased hepatic TG secretion (very low-density 
lipoprotein, VLDL) and/or decreased intestinal TG secretion (chylomicrons and VLDL) 
(38).  This inhibition of TG secretion reduces the amount of TG that is present in the 
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plasma, thus lowering PPL.  Study also found n-3FA supplementation increased 
lipoprotein lipase activity (LPLa) in human subjects (79).  Since lipoprotein lipase (LPL) 
is the major enzyme to hydrolysis circulating TG, by increasing LPLa, n-3FA attenuates 
PPL.  
Exercise reduces PPL          
     Ziogas et al (95) demonstrated that exercise training was associated with significantly 
lowered PPL.  Zhang et al (97) showed that a session of aerobic exercise before ingestion 
of a high-fat meal significantly decreased PPL up to 50%, and elevated high density-
lipoprotein cholesterol (HDL-C) concentrations.  Others also have observed a marked 
attenuating effect of aerobic exercise on PPL (88).  The reduction of PPL is due to an 
increase in LPLa (96).  LPL is an enzyme that is attached to the endothelial layer of the 
vascular walls of the capillary beds within skeletal muscle and adipose tissue.  Exercise 
enhances LPLa in skeletal muscle and adipose tissues (13, 69).  Exercise was also found 
to induce LPL gene expression in skeletal muscle (51, 77).    
Exercise, fish oil, and PPL      
     In a study in which fish oil was coupled with exercise, Warner et al (93) found that 
exercising 3 days/wk for 12 wk in conjunction with fish oil supplementation can lower 
fasting TG levels.  However, they only measured fasting TG, without measuring PPL TG.  
Thomas et al (85) found the combination of fish oil and an acute exercise had no effect 
on the PPL TG response in sedentary subjects; the combination of the two treatments 
produced interference.  But Smith et al (79) found in trained subjects, the combination of 
fish oil supplementation with an acute exercise bout produced an additive effect on 
attenuating PPL TG.  These results raised two important questions: 1) Is the 
  
 
5
recommendation of combining fish oil supplementation with exercise training valid in 
sedentary people? 2) How long does it take for this interference effect to convert to a 
beneficial combination in sedentary people who start exercise training?  The answers to 
these questions would be scientifically relevant to the large population of sedentary 
people recommended by physicians to take exercise and fish oil supplements.  This 
recommendation is published in many popular magazines.   
     Halle et al (35) exercise trained subjects for 4wk, and found plasma TG was 
significantly decreased.  Hamazaki et al (36) found plasma TG decreased after 4 weeks 
fish oil supplementation.  Based on these previous studies, we hypothesize that fish oil or 
exercise for 4 weeks should decrease TG significantly.  However, no studies have 
combined these treatments.   
Exercise, fish oil, and inflammation 
Exercise and inflammation   
     The pathology of atherosclerosis may be initiated by inflammation.  Monocytes 
adhere to endothelialcells, and subsequently transmigrate into the vascular intima as a 
key event in the development of atherosclerosis.  Exposure of leukocyte and vascular 
adhesion molecules such as ICAM-1 on the surface of monocytes and endothelial cells 
causes them to adhere.  High blood TG is correlated to the expression of cell adhesion 
molecules; thus TG also contributes to atherosclerosis (45).  By attenuating the levels of 
PPL TG, exercise indirectly inhibits development of atherosclerosis.  Acute exercise 
induces inflammation in the body (59, 67, 83).  However, long-term aerobic exercise 
training seems to inhibit inflammatory processes and thus reduces the risk of lifestyle 
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related diseases (57, 64).  There were studies (14, 15) which explored the anti-
inflammatory effect of different types of exercise, but the conclusion has yet to be drawn.     
Fish oil and inflammation  
     Epidemiological studies have shown that men who ate at least some fish weekly had a 
lower mortality rate from CHD than men who did not (47).  The Physicians’ Health 
Study reported an inverse relationship between blood levels of long-chain omega-3 fatty 
acids and risk of sudden death in men without a history of cardiovascular disease (CVD) 
(2).   
     Available randomized controlled trials show n-3FA reduced overall mortality, 
mortality due to myocardial infarction, and sudden death in patients with CHD (55, 56).  
There was in vitro evidence that DHA reduced endothelial expression of ICAM-1and IL-
6 in stimulated cells (23, 24). 
     Another potential antiatherogenic mechanism of omega-3 fatty acids is their 
interference with the arachidonic acid cascade that generates a wide variety of 
eicosanoids.  EPA not only can replace arachidonic acid in phospholipid bilayer, but it is 
also a competitive inhibitor of cyclooxygenase, reducing the production of the 
prostaglandins, thromboxanes, and prostacyclin and the leukotrienes (92).  Some studies 
have shown that omega-3 fatty acids may increase the susceptibility of LDL to oxidation 
(39, 81), whereas others have not (12, 42). 
     Adhesion molecules, including ICAM-1 participate in the adhesion of leukocytes on 
endothelium.  Once adherent to endothelium, macrophages, endothelial cells and smooth 
muscles cells produce pleiotropic cytokine.  Pleiotropic cytokine stimulates the 
production of IL-6, which further induces CRP.  Fish oil intake decreases the 
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concentrations of inflammatory markers in the blood; thus it is believed fish oil has anti-
inflammatory effect by decreasing IL-6 level (19, 22, 24).  Eschen and Miles (30, 60) 
suggested the impact of fish oil supplementation on sICAM-1 varied with dose of the oil 
as well as age and gender of the subjects. 
     No studies were found to investigate the combined effect of fish oil and exercise on 
inflammatory markers.  It is possible that for sedentary people, fish oil may attenuate the 
inflammatory effects of starting an exercise program.       
Purpose and Hypothesis   
Purpose:      
     The purpose of the study was to examine:  (1) whether fish oil and exercise training 
together can attenuate PPL in sedentary subjects better than fish oil alone; (2) whether 
fish oil supplementation can attenuate the inflammatory effects of starting exercise in 
previously sedentary subjects.    
Hypothesis: 
In pre treatment PPL and exercise PPL tests: 
Acute exercise 12 hours before high fat meal attenuates PPL TG. 
In non exercise PPL tests: 
After 4 wk treatment:  
(1) Both fish oil supplementation and fish oil plus exercise training will attenuate PPL 
TG, but the combination treatment will attenuate PPL TG better than fish oil 
supplementation alone.   
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(2) Both fish oil supplementation and fish oil plus exercise training will attenuate CRP, 
IL-6 and sICAM-1 induced by exercise, but the combination treatment will attenuate 
CRP, IL-6 and sICAM-1 more. 
In exercise PPL tests: 
After 4 wk treatment: 
(4) a. In sedentary subjects who take fish oil supplement alone, acute exercise will cause    
          interference in PPL.    
      b. Fish oil supplementation plus exercise training will attenuate acute exercise PPL  
          TG better than fish oil supplementation alone. 
(5) Both fish oil supplementation and fish oil plus exercise training will attenuate CRP, 
IL-6 and sICAM-1 induced by acute exercise, but the combination treatment will 
attenuate CRP, IL-6 and sICAM-1 more. 
METHODS  
Subjects   
     22 healthy men and women, age 18 to 55, were recruited to participate in this study.  
There were altogether 37 people signed the consent forms, among them, 22 finished the 
study.  People dropped out the study for the following reasons: 1) failed to carry out 
exercise, 1 subject; 2) blood draw difficulties, 4 subjects; 3) busy schedule, 3 subjects; 4) 
VO2max indicated having good aerobic training , 1 subject; 5) not able to tolerate PPL 
blood draw, 2 subjects; and 6) no specific reason, 6 subjects.  Among the 22 people who 
finished the study, 10 were males, 12 were females.  There were one African American 
(male), two Egyptians (one male, one female), one Asian (female), and all others were 
Caucasians.  The characteristics of the subjects were shown in Table 1.   
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Table 1. Characteristics of subjects  
 
Variables Groups Baseline 
Age FO+ExTr (n=12) 32.2 ± 2.0 
 FO (n=10) 33.1 ± 3.1 
Gender FO+ExTr male=6, female=6 
 FO male=4, female=6 
Cholesterol (mg/dl) FO+ExTr  192.0 ± 8.9 
 FO 182.8 ± 7.7 
Glucose (mg/dl) FO+ExTr  99.2 ± 2.5 
 FO 99.9 ± 2.9 
Body Weight (kg) FO+ExTr  78.0 ± 2.6 
 FO 78.3 ± 2.8 
BMI (kg/m2) FO+ExTr  26.4 ± 0.6 
 FO 26.9 ± 0.8 
VO2max (L/min) FO+ExTr  2.8 ± 0.2 
  FO 2.8 ± 0.3 
 
Note: There was no significant difference between two groups in characteristics of 
subjects 
 
     Subjects were physically sedentary, which was defined as physical exercise less than 
one hour per week within the past 3 months.  Subjects had no more than one major 
cardiovascular disease risk factor determined by American College of Sports Medicine 
(ACSM) or any other disease symptom according to the guideline of ACSM (7).  Their 
body mass index (BMI) was 25-29.9 kg/m2.  No subject was taking any medication or 
fish oil supplement within the past 6 months.  Subjects were required to stop taking 
multiple vitamin and other healthy supplements for 2 wk before they could enroll into the 
study.  
     Before any participant began the testing period of the study, they had their 
responsibilities and obligations to the research explained to them, and gave informed 
consent.  All subjects completed a health screen, informed consent, and exercise/activity 
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questionnaire.  Fasting blood glucose, cholesterol and blood pressure were also checked 
before they could be enrolled.  Women also completed menstrual cycle questionnaires.  
Subjects were compensated.  This study was approved by Health Sciences Institutional 
Research Board. 
Experimental Design             
     A base line PPL (Pre-PPL) was performed on every subject, after a 12h fast overnight.  
Subject took a high fat meal, which consisted of a standardized high fat shake.  Blood 
samples were taken pre, 2h, 4h, 6h, and 8h after the high fat meal.  Subjects also took an 
acute exercise at 60% VO2max 60 min, before 12h fast overnight; another PPL was 
performed afterwards (Ex-PPL).  In exercise PPL trials, blood samples were also taken 
right after exercise bout.  The two postprandial trials were randomized. There was one 
week between these two trials.  Subjects were then randomly divided into two groups; 
group one took fish oil supplementation (4g n-3 FA/day) for 4 wk; group two took fish 
oil supplementation together with exercise (5 times/wk, 45 min/day at 60% VO2max 
(~75%maximal heart rate estimated) for 4 wk.  When the treatment was finished, a non 
exercise PPL (Post-PPL) and an exercise PPL (Post-Ex-PPL) were performed on every 
subject.  The two postprandial trials were randomized. There was one week between 
these two trials.  The timeline of the study is shown in Figure 1.  The timeline of PPL 
trail is shown in Figure 2.  
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Figure1: Study timeline 
Note: Trial 1 and 2 were PPL or Ex-PPL, the order was randomized.  Trial 3 and 4 were 
PPL or Ex-PPL, order was randomized. 
 
 
1h ex a                  ▼ 
 
 12 h fast      
      
 
    0h 2h 4h  6h                       8h 
 
 
Figure 2: PPL trial timeline 
▼ = high fat meal   ↓ = Blood sample    
a For exercise trials, each subject completed a 1 h treadmill exercise at 60% of VO2max, 12 
h before the high fat meal. 
 
Body Mass Index 
     Body weight was measured to the nearest 0.05 kg by using a scale (Toledo Honest 
Weight Inc., Toledo, IA).  Height was measured to the nearest 0.1 cm by using calibrated 
wall chart.  Body mass index (BMI) was calculated by dividing the subjects’ weight in kg 
by the square of their height in m. 
Wk 2-5 
Wk 1 
Wk 6 
Wk 6 
 
Group 1 
Fish oil supplement 
Group 2 
Fish oil + Ex-Tr 
Trial 2 
Trial 3 
Trial 4 
Trial 3 
Trail 4 
Trial 1 
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Diet 
     The three day diet log in the beginning of the study from 10 subjects (4 in FO, 6 in 
FO+ExTr), were collected.  There was no difference between groups in the amount of 
nutritional factors intake, and the portion of each nutritional factors contributed to the 
calories intake (Table 2).  Subjects were instructed to maintain their diet habit during the 
study.  The food intake on the day before the first PPL trial was documented, and kept by 
the subject.  On the days before every PPL trials afterwards, they followed the diet of the 
day before the first PPL trial.    
Table 2.  Dietary characteristics of the subjects 
 
Variable Group Values 
Total Kcal FO (n=4) 2056.0 ± 166.9 
 FO+ExTr (n=6) 2736.2 ± 352.1 
 two groups (n=10) 2464.1 ± 239.5 
CHO (g) FO 258.3 ± 21.1 
 FO+ExTr 317.5 ± 46.1 
  two groups 293.8 ± 29.4 
Protein (g) FO 86.7 ± 10.1 
 FO+ExTr 93.8 ± 7.2 
 two groups 90.9 ± 5.7 
Fat (g) FO 79.3 ± 10.1 
 FO+ExTr 123.5 ± 20.2 
  two groups 105.8 ± 14.2 
Sat Fat (g) FO 23.7 ± 6.6 
 FO+ExTr 37.5 ± 6.8 
 two groups 31.9 ± 5.1 
CHO (% kcal) FO 49.4 ± 2.7 
 FO+ExTr 46.3 ± 3.3 
  two groups 47.6 ± 2.2 
Fat (% kcal) FO 34.0 ± 3.0 
 FO+ExTr 38.8 ± 3.7 
 two groups 36.9 ± 2.5 
Protein (% kcal) FO 16.6 ± 1.7 
 FO+ExTr 14.2 ± 1.1 
  two groups 15.1 ± 1.0 
 
Note: There was no significant difference between two groups in dietary characteristics.  
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High fat meal   
     The size of the high fat meal was based upon the body weight of each subject, and 
contains 1.3g fat, 0.06g proteins and 0.3g of carbohydrate per kg of body weight.  For an 
example, the high fat meal of a 75kg subject contained 97.5g fat, 4.2g protein, and 25.4g 
of carbohydrate; and the total energy provided by the meal was 1087.8 kcal.  This diet 
has been used in other studies of our group (4, 79).   
PPL   
     Subjects were required to stop physical exercise 30 h to 36 h before fasting started in 
non exercise PPL trials.  Subjects who participated in exercise training did 1 h exercise at 
60% VO2max during Ex-PPL to substitute the training session for that day.  Subject 
reported to the lab in the morning, after 12h of fasting overnight.  The body weight of the 
subject was obtained right before the high fat meal was prepared, during each every PPL 
trial.  After the fasting blood samples were taken, subjects ingested the high fat meal.  
Venus blood samples were taken before, 2h, 4h, 6h and 8h after the high fat meal.  
Subjects were allowed to leave the lab after every blood sampling, but they were required 
to only drink water before the blood samples of all the time points were taken.   
Exercise    
A. Exercise PPL.  Each subject reported to the lab 12 hours prior to the high fat meal to 
complete this aerobic exercise session.  The session consisted of exercising on the 
treadmill for 60 min at 60% of their previously determined VO2max.  Heart rate monitor 
(Polar E600, Polar Electro Inc., Woodbury, NY) was used to monitor the heart rate 
during the test.  Subjects started walking at a low intensity treadmill speed that increased 
every minute.  The 60 min session started after the 9 min warm-up.  Treadmill speed was 
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adjusted to allow the heart rate to reach and maintain the 75% HR max.  At the end of the 
exercise session, subjects were allowed to cool down at their own paces to achieve a near 
resting heart rate.  Subjects then started fasting for 12h overnight, and they reported to the 
lab in the morning.  After the fasting blood samples were taken, subjects ingested the 
high fat meal.  Venus blood samples were taken before, 2h, 4h, 6h and 8h after the high 
fat meal.  This test was performed before and after the treatment.  It was performed a 
week before or after each common PPL.   
B. VO2max test.  Each subject completed a VO2max test on a treadmill (Quinton Model 
18-60) to determine baseline fitness status, and appropriate intensity for the submaximal 
exercise training prescription.  The protocol that was used for the VO2max test was 
slightly modified from the protocol that has been previously described by our group (88).  
Initially, subjects warmed up by walking 3.0 mph on the treadmill.  All subjects began 
the first workload stage of the VO2max test at 3.5 mph.  The first workload stage was 
maintained for 2 min.  After the first workload stage, the treadmill speed was increased 
by 0.5 mph/min at the end of each minute until reaching 6.0 mph (beginning of 7th minute 
of test).  The pace (6.0 mph) was held for 1 min and maintained throughout the remainder 
of the test.  After the end of the 7th minute, treadmill grade was increased by 2%/min until 
subjective exhaustion.  The highest VO2 value obtained was considered the subject’s 
VO2max.  Physiological criteria for a VO2max test included a maximal respiratory 
exchange ratio (RER) ≥ 1.1, maximal heart rate within 10% of age predicted maximum, 
and leveling of O2 consumption (≤ 2 ml/kg/min difference between two successive work 
loads).  We required at least two of these criteria to be met in order for the highest 
VO2max value to be considered a true VO2max.  
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     Gas collection and analysis during VO2max tests were performed in the Exercise 
Physiology Lab using the Parvo Medics TrueOne 2400 metabolic cart (Parvo Medics Inc, 
Sandy, UT).  The headgear used for gas collection during treadmill maximal tests was a 
Hans Rudolph head support (Hans Rudolph model # 2726, Kansas City, MO) that held a 
bi-directional valve attached to a rubber mouthpiece.  The valve was connected to 4 ft. of 
tubing that was directly connected to the pneumotach of the TrueOne 2400 metabolic 
cart.     
C. Exercise training.  Subjects were randomly assigned to fish oil supplementation (FO 
group) or exercise training and fish oil supplementation group (FO+ExTr group).  
Subjects in FO+ExTr group participated walking or jogging on treadmill 5 time/wk, 45 
min/day, for 4 wk at 60% VO2max (75% HR max).  The intensity of the training was 
monitored using heart rate (with the goal 75% HR max as measured on the VO2max test) 
and Rating of Perceived Exertion (RPE).  The training followed a one week progression: 
In wk 1 subjects were trained 30 min, 60% VO2max (75% HR max) for the first three 
days; by the end of wk 1, they started training at 45min, 60% VO2max; and maintain this 
intensity 5d/wk, for the rest of the 4 wk training section.  Most of the exercise trainings 
were carried out under the supervision in Exercise Physiology Lab.  For every subject, 
one training session per week was allowed to be done on his/her own.  Subject borrowed 
heart rate monitor from the lab, monitored his/her heart rate when walking on a treadmill 
or outdoor.  However, most of the subject came to the lab every time.             
Fish oil supplementation     
     After the completion of the Pre-test which including baseline PPL and Ex-PPL, fish 
oil capsules (Super EPA-500, Bronson Pharmaceutical, St. Louis, MO) were provided to 
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all the subjects once a week for 4wk.  Each capsule contained 300 mg of EPA and 200 
mg of DHA (500 mg n-3FA/capsule).  Every subject took 8 capsules, which equaled to 
4g n-3 FA/day.  Subjects were instructed to take two capsules with each meal (breakfast, 
lunch, and dinner) and two before going to bed.   
     Supplement was provided to the subjects once a week.  Pill counts were used to track 
compliance in taking the supplement.  Each subject was provided with 2 or 3 more 
capsules every week than they supposed to take and the number was recorded.  When 
they returned to the lab for more capsules each week, the number of remaining capsules 
was counted.  Failure to ingest the required number of capsules may have resulted in 
dismissal from the experiment.  Overall subject compliance was calculated by taking the 
average of all individual subject compliances.   
     Compliance = (Amount taken/Amount should have taken)*100 
Blood Collection    
     Blood was collected from a butterfly needle inserted into an antecubital vein.  In every 
time point, 10 ml blood samples were collected into a 10ml tubes containing EDTA 
(anticoagulant and chelating agent).   
     All EDTA blood samples were separated by centrifugation at 40C for 15 min at 2000g 
in a Marathon 22100R centrifuge (Fisher Scientific, Pittsburgh, PA).  The separated 
plasma was transferred to 0.5ml and 1.8 ml cryogenic vials and stored at -700C for later 
analysis.  
     Plasma Volume.  Hematocrit (Hct) values were used to calculate plasma volume (PV) 
changes.  Hct was measured in 4 subjects before acute exercise and at every time point of 
Ex-PPL trial.  % change of plasma volume in comparing to pre exercise was calculated as 
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previously described by Beaumont et al (11).  The changes in PV were assessed to 
determine if corrections were necessary.   
     Hct was measured immediately following the blood draws.  Before the blood was 
transferred to vacutainers, two micro hematocrit capillary tubes were filled two-thirds full 
with whole blood and sealed with capillary tube sealant.  The capillary tubes were spun in 
a micro hematocrit centrifuge (Model MB, International Equipment Company, Needham 
Heights, MA) for 3 min.  Hct was measured with a hematocrit tube reader (Model CR, 
International Equipment Company, Needham Heights, MA), using the directions 
provided by the manufacturer.    
Plasma TG Analysis  
     Plasma TG concentration was measured to determine the PPL response.  The PPL 
response was defined as the total area under the TG curve (TG-AUCT), the incremental 
TG-AUC (TG-AUCI), and the TG peak response.  The TG-AUCT was calculated using 
the trapezoidal method as described by Tai (84). The TG-AUCI also was calculated using 
the trapezoidal method, but the baseline TG values were subtracted from each TG value 
before completing the calculations.  The TG-AUC was calculated by the trapezoidal 
method using the following formula: 
           TG-AUCT = 0.5*[X1(y0+y2) + X2(y2+y4) + X3(y4+y6) + X4(y6+y8)] 
           TG-AUCI  = 2* (y2 + y4 + y6) + y8 – 7*y0  
           where: 
           X1= x2-x0, X2 = x4-x2, X3 = x6-x4, and X4 = x8-x6 
           xn = n hour 
           yn = the TG concentration at n hours 
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The TG peak response was defined as the difference between greatest plasma TG 
concentration minus the 0 h plasma TG value. 
     TG concentrations were measured from the blood drawn at pre, 2, 4, 6, and 8 h post 
high fat meal.  This was done to determine PPL response to the meal.  The area under the 
curve and peak response determined the magnitude of the response.  Plasma TG was 
measured enzymatically using a diagnostic kit (InfinityTM, Thermo DMA, Inc. Louisville, 
CO).  Measurements are made using a Beckman DU 530 spectrophotometer (Beckman 
Instruments Inc. Fullerton, CA) using known standards.  Infinity TM TG Reagent (1.0 ml) 
was pipette into 13*100disposable culture tubes.  Standard (10 µl) (TR 22923, Thermo 
DMA, Inc. Louisville, CO) and plasma (10 µl) were pipetted into appropriately labeled 
tubes.  After the addition of the reagent and the plasma, the tubes were briefly vortexed 
and incubated for five minutes at 370C.  The absorbance of TG was read at 520 nm.  
Plasma TG concentration was calculated using the following equation: (absorbance of 
sample/absorbance of calibrator) * concentration of the calibrator (200 mg/dl).  In order 
to eliminate inter assay variability; all samples from a single subject were analyzed 
together for each assay.  For this procedure, the within assay mean coefficient of 
variation (CV) was 1.4%.   
HDL Analysis   
     Total HDL-C and HDL3-C were measured enzymatically using diagnostic kits.  All 
samples for an individual subject were included in the same run, with one to two 
subjects’ samples being run together in the same day.  InfinityTM Cholesterol Reagent 
(1.0 ml) was pipetted into appropriately labeled falcon tubes for each plasma sample (500 
µl).  A 1:1 heparin/MnCl2 (50 µl) solution was added to each tube and vortexed.  
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Following 20 min of refrigerated incubation, samples were centrifuged at 1500g for 20 
min at 00C. 
     Supernatant (200 µl) was pipetted into a new set of falcon tubes for each sample.  
Dextralip 15 (20 µl) solution was added to each sample, which were then vortexed and 
incubated at room temperature for 20 min.  While those tubes were incubating, the 
supernatant remaining in the first set of falcon tubes was analyzed for total HDL-C. 
     Supernatant of each sample (50 µl) from the first set of tubes was combined with 
InfinityTM Cholesterol Reagent (1.0 ml) and incubated for 5 min at 370C.  Samples were 
then transferred into cuvettes and placed into the spectrophotometer read at 450 nm.  
Total HDL-C was calculated using the following equation: (absorbance of 
sample/absorbance of calibrator) * concentration of the calibrator (50 mg/dl) * 1.10. 
     Following the incubation period, the second set of falcon tubes were again centrifuged 
at 1500g for 20 min at 200C.  Samples were then analyzed for HDL3-C concentration in 
the identical manner total HDL-C was analyzed.  HDL3-C was calculated using the 
following equation: (absorbance of sample/absorbance of calibrator) * concentration of 
the calibrator (50 mg/dl) * 1.21.  HDL2-C was calculated using the following equation: 
total HDL-C (mg/dl) - HDL3-C (mg/dl).  The CV for HDL-C concentration was 0.85%.   
LDL-C Calculation         
     Plasma LDL-C concentration was calculated by using the Friedewald equation (30).  
LDL-C (mg/dl) = TC (mg/dl) – HDL-C (mg/dl) - TG/5 (mg/dl). 
CRP, IL-6 and sICAM-1 Assays  
     Commercially available solid phase enzyme-linked immunosorbent assay (ELISA) 
based on the sandwich principle was used to determine fasting serum concentrations of 
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the CRP (#30-9710S, ALPCO Diagnostics, Windham, NH), IL-6 (#88-7066, eBioscience 
San Diego, CA) and sICAM-1 (BBE-1B, R & D Systems Inc. Minneapolis, MN).  In 
brief, antibodies specific for each marker were pre-coated onto a microtitre plate.  
Standards and samples were pipetted into the wells and the immobilized antibody binds 
any marker present.  After washing away any unbound substances, an enzyme-linked 
antibody specific for the marker was added to the wells.  Following a second wash to 
remove any unbound antibody-enzyme reagent, an acidic substrate solution was added to 
the wells and color develops in proportion to the amount of marker bound in the initial 
step.  A stop solution was added and the intensity of color (read at wavelengths of 450 
nm and 630 nm reference) is measured.  The coefficient of variation for each of these 
variables was less than 6%. 
Statistical Analysis 
     2-way repeated measures ANOVA was performed by using SigmaStat 2.03 under the 
following conditions: 
(1) Within non exercise PPL data, the two factors were groups (fish oil vs. fish oil plus 
exercise training) and time (pre treatment vs. post treatment). 
(2) Within exercise PPL data, the two factors were groups (fish oil vs. fish oil plus 
exercise training) and time (pre treatment vs. post treatment). 
(3) HDL-C values of the two groups in the same kind of PPL trial, pre and post treatment.  
HDL-C values of the two groups in PPL and Ex-PPL trials before treatment as well as 
after treatment.  Same method was applied to HDL2-C and HDL3-C values. 
(4) LDL-C values of the two groups in fasting samples, pre and post treatment.   
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(5) CRP values of the two groups in fasting samples, pre and post treatment.  CRP values 
of the two groups in 12h after acute exercise samples, pre and post treatment. 
(6) IL-6 values of the two groups in Ex-PPL 2h samples, pre and after the treatment. 
(7) sICAM-1 values of the two groups in fasting samples, pre and post treatment.      
     One-way ANOVA was performed by using SigmaStat 2.03 in: 
(1) Comparing the difference between the two treatment groups in age, cholesterol, 
glucose, body weight, BMI, waist:hip ratio, % fat, VO2max, maxHR, and the dietary 
characteristics before treatment.   
(2) Comparing the PPL TG values in the same trial of the two groups before treatment as 
well as after treatment.     
     One-way repeated measures ANOVA was performed by using SigmaStat 2.03 in:  
(1) Comparing PPL TG values in PPL and Ex-PPL trials within the same treatment group 
in pre treatment as well as in post treatment.   
(2) Comparing PPL TG in same group, same PPL trial pre and post treatment values.  
(3) HDL-C values within the same treatment group, same kind of PPL trial, pre and post 
treatment.  Same method was applied to HDL2-C and HDL3-C values.  
(4) CRP values of same group, in fasting samples and 12h after acute exercise samples.  
RESULTS 
     PPL samples were successfully taken in all time points of 21 subjects (10 in FO group, 
11 in FO + ExTr group).  There was one subject missed 8h time point sampling in PPL 
trial in pre testing, due to the difficulty of venipuncture.  The value was estimated by 
using the following equation: 8h TG Value of the subject = (Mean 8h TG of FO+ExTr 
group / Mean 0h TG of FO+ExTr group) * 0h TG of the subject.  Overall subject 
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compliance was 104.0% since most subjects left no fish oil capsules when they came to 
refill, although they were provided 2 or 3 more.    
Body Composition 
     There were no differences in body weight, BMI, waist/hip ratio, % fat, VO2max, and 
maxHR between the two groups before treatment.  There was no change of body weight, 
BMI, and waist/hip ratio in both groups after the treatment.  % fat was significantly 
decreased in FO+ExTr group (Table 3). 
Aerobic Capacity 
     There was no significant change of VO2max and maxHR in FO group.  In FO+ExTr 
group VO2max were significantly increased, while maxHR did not change after the 
treatment (Table 3).    
Plasma TG      
Pre treatment   
     TG-AUCT, TG-AUCI, TG-PeakT and TG-PeakI values are shown in Table 4.  There 
were no significant differences in any PPL parameters (Table 4, wk 0), and TG values at 
any time points (Table 5, wk 0) between two groups in PPL trials before the treatment 
(Table 6).  There was no significant difference in any PPL parameters (Table 4, wk 0), 
and TG values at any time points (Table 5, wk 0) between two groups in Ex-PPL before 
treatment (Table 6).  There were no differences in any PPL parameters (Table 4, wk 0), 
and TG values at any time points (Table 5, wk 0) between PPL and Ex-PPL trial within 
the same group or two groups together before treatment (Table 6).       
Post treatment   
  
 
23
     The summary of the PPL TG changes is in Table 6.  There were no significant 
differences in any PPL parameters between two groups in PPL trials after the treatment 
(Table 4, wk 4).  There were significant changes in TG-AUCT in two groups together 
after the treatment, in PPL trial (Table 4, wk 0 vs. wk 4).   
     There was no significant difference in any PPL parameters between two groups after 
treatment, in Ex-PPL (Table 4, wk 4).  In FO+ExTr group, there were significant changes 
in TG-AUCT and TG-PeakT after the treatment, in Ex-PPL (Table 4, wk 0 vs. wk 4, 
Figure 7, Figure 8).  There were significant changes in TG-AUCT and TG-PeakT in two 
groups together after the treatment, in Ex-PPL trial (Table 4, wk 0 vs. wk 4).  There were 
no differences in any PPL parameters between PPL and Ex-PPL trial within the same 
group or two groups together after treatment (Table 4, wk 4).  
     Among PPL trials, in FO group, TG was significantly lower at 0h and 4h after 
treatment (Table 5, Figure 3); in FO+ExTr group, TG was significantly lower at 0h and 
8h after treatment (Table 5, Figure 4).  There were significant decreases of TG in 0h, 4h 
and 8h in two groups together after the treatment, in PPL trials (Table 5, Figure 9). 
     Among Ex-PPL trials, in FO group, there were significant decreases of PPL TG at 0h 
and 6h after the treatment (Table 5, Figure 5).  In FO+ExTr group, there were significant 
decreases of PPL TG at 0h, 2h, 4h, and 6h after the treatment (Table 5, Figure 6).  TG 
peaked at 2h in both pre and post Ex-PPL trials. There were significantly decreases of TG 
in all 5 time points in two groups together after the treatment in Ex-PPL trial (Table 5, 
Figure 9). 
HDL-C and subfractions  
Pre treatment 
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     HDL2-C and HDL3-C values were significantly different in two groups together 
between fasting samples and exercise samples (12h after acute exercise) (Table 7, wk 0). 
Post treatment 
     There were significant increases of HDL-C and HDL2-C and decrease of HDL3-C in 
two groups together, in fasting samples after the treatment (Table 7).  HDL2-C and 
HDL3-C values were significantly different in two groups together between fasting 
samples and exercise samples (12h after acute exercise) (Table 7).  There was a 
significant increase of HDL2-C, but HDL-C and HDL3-C were unchanged in FO group 
(Table 7, Figure 10).  There were significant increases of HDL-C and HDL2-C and 
decreases of HDL3-C in FO+ExTr group after the treatment (Table 7, Figure 11).   
LDL-C 
     There was no significant change of LDL-C in each group, or two groups together after 
the treatment (Table 8). 
CRP      
     There were no differences of CRP in fasting samples and exercise samples (12h after 
acute exercise) between the two groups, before treatment (Table 9, wk 0).  There were no 
significant changes of CRP in fasting samples in both groups, after the treatment (Table 
9).  In the exercise samples (12h after acute exercise), there were no significant changes 
in CRP values in both groups, after treatment (Table 9).  Within the same treatment 
group, there was no significant difference between fasting samples vs. exercise samples 
pre or post treatment in CRP values (Table 9).   
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IL-6    
     IL-6 values were undetectable in the exercise samples (12h after acute exercise).  In 
Ex-PPL 2h samples, there was no significant difference of IL-6 values before and after 
the treatments (Table 10). 
sICAM-1  
     There was no significant difference in sICAM-1 values in fasting samples before and 
after the treatments (Table 11). 
Plasma Volume 
     There was a significant difference of % change of plasma volume in 6h, comparing 
with 0h (Table 12).  The trend of plasma volume change showed a decrease  
after exercise and then gradually back up after 16h to 18h.      
 
 
Table 3. Changes in characters of subjects  
Variables Groups 0 weeks 4 weeks 
Body Weight (kg) FO 78.3 ± 2.8 78.4 ± 2.4 
 FO+ExTr 78.0 ± 2.6 78.5 ± 2.6 
BMI (kg/m2) FO 26.9 ± 0.8 26.9 ± 0.7 
 FO+ExTr 26.4 ± 0.6 26.6 ± 0.6 
Waist : Hip Ratio FO 0.80 ± 0.02 0.81 ± 0.02 
 FO+ExTr 0.81 ± 0.02 0.81 ± 0.02 
% fat (skin fold) FO 28.0 ± 4.0 26.3 ± 4.0 
 FO+ExTr 26.2 ± 2.3 24.1 ± 2.1* 
VO2max (L/min) FO 2.8 ± 0.3 2.9 ± 0.3 
 FO+ExTr 2.8 ± 0.2 3.0 ± 0.2* 
max HR FO 190.2 ± 4.0 187.9 ± 3.7 
  FO+ExTr 184.7 ± 4.5 183.5 ± 4.5 
 
Values are reported as Means± SE.  * Significant difference between pre and post 
treatment in each group, P<0.05. 
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Table 4. PPL TG values of each group and two groups together 
 
Group Trial Measure Week 0 Week 4 
FO PPL TG-AUCT 1319.2 ±  178.9 1013.1 ± 53.3 
 PPL TG-AUCI 390.9 ± 113.2 255.2 ± 42.2 
 PPL TG-PeakT 214.1 ± 29.3 163.0 ± 7.8 
 PPL TG-PeakI 98.0 ± 20.9 68.3 ± 7.1 
 Ex-PPL TG-AUCT 1321.6 ± 143.8 1077.5 ± 85.8 
 Ex-PPL TG-AUCI 344.2 ± 64.4 273.1 ± 55.2 
 Ex-PPL TG-PeakT 206.0 ± 24.5 177.5 ± 15.8 
  Ex-PPL TG-PeakI 83.8 ± 14.3 76.9 ± 12.6 
FO + ExTr PPL TG-AUCT 1438.9 ± 183.8 1354.7 ± 226.3 
 PPL TG-AUCI 347.8 ± 82.0 418.7 ± 103.6 
 PPL TG-PeakT 207.9 ± 27.1 212.1 ± 39.5 
 PPL TG-PeakI 71.6 ± 14.3 95.1 ± 24.5 
 Ex-PPL TG-AUCT 1457.4 ± 206.9 1153.6 ± 127.6* 
 Ex-PPL TG-AUCI 327.6 ± 92.9 273.4 ± 31.6 
 Ex-PPL TG-PeakT 217.9 ± 28.9 169.9 ± 19.2* 
 Ex-PPL TG-PeakI 76.7 ± 13.8 59.8 ± 7.9 
two groups PPL TG-AUCT 1384.5 ± 126.7 1199.4 ± 128.7* 
 PPL TG-AUCI 367.4 ± 66.6 344.4 ± 61.1 
 PPL TG-PeakT 210.7 ± 19.4 189.8 ± 22.1 
 PPL TG-PeakI 83.6 ± 12.3 82.9 ± 13.8 
 Ex-PPL TG-AUCT 1395.7 ± 128.4 1119.0 ± 78.5* 
 Ex-PPL TG-AUCI 335.2 ± 57.2 273.2 ± 29.6 
 Ex-PPL TG-PeakT 212.5 ± 18.9 173.3 ± 12.4* 
  Ex-PPL TG-PeakI 79.9 ± 9.7 67.6 ± 7.2 
 
Values are reported as Means± SE.  * Significant difference between pre and post 
treatment within the same row, P< 0.05.  There was no significant change between two 
groups in PPL trials before the treatment, as well as after treatment.  There was no 
significant difference between two groups in Ex-PPL before treatment, as well as after 
treatment.  There was no change between PPL and Ex-PPL trial within the same group or 
two groups together before treatment, as well as after treatment.     
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Table 5.  PPL TG values at every time point 
 
Group Trial Measure Week 0 Week 4 
FO PPL 0h 116.0 ± 10.7 94.7 ± 7.8* 
 Ex-PPL  122.2 ± 14.1 100.6 ± 9.1* 
FO+ExTr PPL  136.4 ± 14.7 117.0 ± 16.2* 
 Ex-PPL  141.2 ± 16.3 110.0 ± 12.9* 
two groups PPL  127.1 ± 9.4 106.9 ± 9.6* 
  Ex-PPL   132.6 ± 10.9 105.7 ± 8.1* 
FO PPL 2h 191.6 ± 25.2 154.7 ± 11.1 
 Ex-PPL  190.3 ± 21.8 168.9 ± 15.7 
FO+ExTr PPL  187.2 ± 21.5 179.7 ± 22.6 
 Ex-PPL  203.8 ± 25.7 159.5 ± 17.4* 
two groups PPL  189.2 ± 16.0 168.3 ± 13.3 
  Ex-PPL  197.7 ± 16.8 163.8 ± 11.6* 
FO PPL 4h 184.1 ± 22.2 132.8 ± 8.0* 
 Ex-PPL  193.6 ± 22.9 146.3 ± 16.3 
FO+ExTr PPL  203.7 ± 27.6 192.0 ± 40.5 
 Ex-PPL  192.4 ± 29.4 162.3 ± 19.1* 
two groups PPL  194.8 ± 17.8 165.1 ± 22.9* 
  Ex-PPL   193.0 ± 18.7 155.0 ± 12.6* 
FO PPL 6h 164.3 ± 33.9 123.4 ± 10.2 
 Ex-PPL  158.9 ± 19.6 127.5 ± 10.6* 
FO+ExTr PPL  187.2 ± 27.8 184.6 ± 36.5 
 Ex-PPL  186.5 ± 30.3 137.6 ± 14.7* 
two groups PPL  176.8 ± 21.2 156.8 ± 21.1 
  Ex-PPL  173.9 ± 18.6 133.0 ± 9.2* 
FO PPL 8h 123.3 ± 16.9 96.6 ± 6.3 
 Ex-PPL  113.7 ± 11.1 91.7 ± 7.1 
FO+ExTr PPL  146.4 ± 18.7 125.2 ± 17.3* 
 Ex-PPL  150.6 ± 26.3 124.9 ± 16.6 
two groups PPL  135.9 ± 12.7 112.2 ± 10.1* 
  Ex-PPL   133.8 ± 15.4 109.8 ± 10.1* 
 
Values are reported as Means± SE.  * Significant difference between pre and post 
treatment within the same row, P< 0.05.  There was no change between PPL and Ex-PPL 
trial within the same group or two groups together before treatment, as well as after 
treatment.           
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Table 6. Summary of PPL TG changes 
 
 
 
 
Time (hour)
0h 2h 4h 6h 8h
Tr
ig
ly
ce
rid
es
 (m
g/
dl
)
0
50
100
150
200  pre PPL
post PPL 
* 
* 
FO group 
Meal 
     
        
Figure 3.  TG changes at time points after high fat meal in FO group, before and after 
treatment.  Values are reported as Means ± SE.  * Significant difference between pre and 
post samples, p<0.05. 
 
 
Pre treatment Post treatment
FO vs. FO+ExTr ↔ ↔
FO
PPL TG↓ 0h, 4h
Ex-PPL TG↓ 0h, 6h
FO+ExTr
PPL TG↓ 0h, 8h
Ex-PPL TG-AUCT↓, TG-PeakT↓
TG↓ 0h, 2h, 4h, 6h
2 groups
PPL TG-AUCT↓
TG↓ 0h, 4h, 8h
Ex-PPL TG-AUCT↓, TG-PeakT↓
TG↓ 0h, 2h, 4h, 6h, 8h
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Figure 4. TG change at 5 time points after high fat meal in FO+ExTr group before and 
after treatment.  Values are reported as Means ± SE. * Significant difference between pre 
and post samples, p<0.05. 
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Figure 5. TG changes at time points in FO group, Ex-PPL trail pre vs. post treatment.  
Values are reported as Means ± SE.  * Significant difference between pre and post 
samples, p<0.05. 
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Figure 6. TG changes at time points in FO+ExTr group, Ex-PPL trail pre vs. post 
treatment.  Values are reported as Means ± SE.  * Significant difference between pre and 
post samples, p<0.05. 
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Figure 7. TG AUCT in Ex-PPL pre vs post in each group.  Values are reported as Means 
± SE.  * Significant difference between pre and post samples, p<0.05. 
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Figure 8. TG PeakT in Ex-PPL pre vs post in each group.  Values are reported as Means ± 
SE.  * Significant difference between pre and post samples, p<0.05. 
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Figure 9.  TG values of 5 time points of two groups together in PPL and Ex-PPL trials 
before and after treatment.  Values are reported as Means ± SE (Table 5). * Significant 
difference between pre and post PPL, p<0.05.  a Significant difference between pre and 
post Ex-PPL, p<0.05.  There was no significant difference between PPL and Ex-PPL in 
pre testing or in post testing.   
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Table 7. HDL-C and subfraction values  
 
Group Trail HDL-C (mg/dl) HDL2-C (mg/dl) HDL3-C (mg/dl)
week 0 week 4 week 0 week 4 week 0 week 4
FO Non Exerc. 50.3 ± 3.6 51.7 ± 4.0 16.6 ± 2.6 19.8 ± 3.4* 33.7 ± 1.3 31.9 ± 1.0
FO+ExTr Non Exerc. 53.7 ± 5.1 57.4 ± 5.4* 20.3 ± 3.6 26.8 ± 4.2* 33.4 ± 1.9 30.6 ± 1.4*
2 groups Non Exerc. 52.2 ± 3.2 54.8 ± 3.4* 18.6 ± 2.3 23.6 ± 2.8* 33.6 ± 1.1 31.2 ± 0.9*
FO Exercise 51.3 ± 4.8 51.9 ± 4.2 12.9 ± 2.9 15.7 ± 3.2 38.4 ± 2.1 36.2 ± 1.2
FO+ExTr Exercise 52.7 ± 4.8 54.4 ± 5.0 14.1 ± 2.8 19.8 ± 3.8 38.6 ± 2.3 34.6 ± 1.9
2 groups Exercise 52.1 ± 3.4 53.3 ± 3.3 13.6 ± 2.0**17.9 ± 2.5**38.5 ± 1.5**35.4 ± 1.1** 
 
Values are reported as Means ± SE.  FO group, n=10; FO+ExTr group, n=12.   
* Significant difference after the treatment within the same group.  ** Significant 
difference between non exercise and exercise trial within the same group, p< 0.05. 
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Figure 10. HDL-C and subfraction before and after the treatment in FO group.  Values 
are reported as Means ± SE.  * Significant change between pre and post samples, p<0.05. 
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Figure 11. HDL-C and subfraction before and after the treatment in FO+ExTr group.  
Values are reported as Means ± SE.  * Significant change between pre and post samples, 
p<0.05. 
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Table 8.  Calculated LDL-C values  
 
Group LDL-C week 0 (mg/dl) LDL-C week 4 (mg/dl) 
FO (n=10) 109.4 ± 7.1 106.4 ± 6.3 
FO+ExTr (n=12) 111.1 ± 7.2 117.7 ± 4.6 
two groups (n=22) 110.3 ± 4.9 112.5 ± 3.9 
 
Values are reported as means ± SE.  There was no significant change between pre and 
post treatment. 
 
 
Table 9. Plasma CRP concentrations  
 
Group Measurement CRP wk 0 (mg/L) CRP wk 4 (mg/L) 
FO (n=10) non exerc. 4.6 ± 1.9 5.7 ± 1.4 
 exercise* 3.7 ± 1.3 6.7 ± 2.7 
FO+ExTr (n=12) non exerc. 4.0 ± 2.3 3.1 ± 1.4 
 exercise 3.1 ± 1.6 3.2 ± 1.2 
two groups (n=22) non exerc. 4.3 ± 1.5 4.3 ± 1.0 
  exercise 3.4 ± 1.0 4.8 ± 1.4 
 
Values are reported as means ± SE.  There was no significant change between pre and 
post treatment.  There was no significant change between non exercise and exercise 
samples pre treatment, as well as post treatment.  * 12h after acute exercise. 
 
 
Table 10.  Plasma IL-6 concentrations in Ex-PPL 2h samples 
 
Group IL-6 wk 0 (pg/ml) IL-6 wk 4 (pg/ml) 
FO (n=10) 2.7 ± 0.2 2.9 ± 0.2 
FO+ExTr 2.9 ± 0.4 (n=6) 2.8 ± 0.2 (n=10) 
 
Values are reported as means ± SE.  IL-6 was only detectable in 6 subjects before 
treatment and in 10 subjects after treatment in FO+ExTr group.  There was no significant 
change between pre and post treatment.   
 
 
Table 11. Plasma concentration of sICAM-1 
 
Group sICAM-1 wk 0 (ng/ml) sICAM-1 wk 4 (ng/ml) 
FO (n=10) 60.9 ± 8.3 56.6 ± 7.8 
FO+ExTr (n=12) 48.8 ± 10.5 47.2 ± 9.1 
two groups (n=22) 54.3 ± 6.8 51.4 ± 6.1 
 
Values are reported as means ± SE.  There was no significant change between pre and 
post treatment.   
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Table 12. Hct and plasma volume pre and post exercise bout 
 
Subject Variable Pre Ex 0h 2h 4h 6h 8h
n=4 Hct 42.1 ± 1.3 43.2 ± 1.3 42.6 ± 2.0 41.9 ± 1.9 42.3 ± 1.3 43.0 ± 1.6
n=4 % change in PV -4.1 ± 1.3 -1.5 ± 3.4 1.2 ± 3.6 -0.6 ± 1.3* -3.2 ± 2.6  
 
Note: Values are reported as Means ± SE.  * Significant difference between 6h and 0h, 
p<0.05. 
 
DISCUSSION 
     As reported in the results, the characteristics of the subjects in FO group did not 
change, while in FO+ExTr group %fat decreased, VO2max improved.  Subjects were 
required to maintain the diet habit, but without checking diet again at the end of the 
study, it was unclear how much they kept the diet habit; and this was a limitation of the 
study.  However, because there was no change in body weight, BMI, and waist:hip ratio 
after treatment in both groups (Table 3), it was reasonable to believe the subjects did not 
change their dietary habits.  Exercise training improved the body composition without 
changing BMI and waist/hip ratio.  Fish oil supplement on the other hand, caused a 
boarder line decrease in %fat (P=0.084).  Four weeks of aerobic exercise training 
significantly improved VO2max of the previously sedentary subjects, while fish oil 
showed no improvement (Table 3).  Similar result of combination treatment improving 
aerobic capacity was also shown in the study by Warner et al (93).  The results of 
improved VO2max in combination treatment indicated fish oil supplementation plus 
aerobic exercise training improved aerobic capacity in sedentary subjects.  Since the 
improvement of body composition and aerobic capacity will benefit the prevention of life 
style related diseases, it would be a better way to provide combination treatment on the 
sedentary subjects on this variable.   
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PPL       
     Our group has done fish oil and PPL studies in sedentary people and recreational 
trained people.  In recreational trained subjects, Zhang et al (97) found acute exercise 12h 
before high fat meal attenuated TG AUC by 51%.  Smith et al (79) found fish oil 
supplement (4 g/day, 5 wk) plus acute exercise attenuated PPL TG more effectively than 
fish oil alone.  These results indicated acute exercise in combination of fish oil 
supplementation had an additive effect on attenuating PPL TG, in recreational trained 
subjects.   
     In sedentary subjects, Thomas et al (85) provided subjects fish oil 4 g/day for 3 wk.  
They found a significantly decreased baseline TG in fish oil alone and fish oil in 
combination with acute exercise two groups together after the treatment.  However, there 
were no differences in PPL parameters in any group when comparing with control group.    
Our group has demonstrated acute exercise 12h before high fat meal attenuated PPL TG 
(88, 97), but fish oil in combination with acute exercise did not attenuate PPL TG (85), 
suggesting that fish oil supplementation had interference with acute exercise in 
attenuating PPL TG.  According to these results, one could conclude: 1) 3 wk fish oil 
supplementation was not sufficient to attenuate PPL TG.  2) fish oil supplementation had 
interference with acute exercise in attenuating PPL TG, in sedentary subjects.  Warner et 
al (93) trained sedentary subjects (3 d/ wk), and having them taking fish oil supplement 
(17.5 ml/day) for 12 wk.  They found both fish oil alone and fish oil in combination with 
exercise training attenuated fasting TG.  However there were no differences between 
these two groups.  They did not investigate PPL TG.  According to the results of these 
previous studies, it was unclear how fish oil supplementation in combination with 
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exercise training influences PPL TG in sedentary subjects, especially when they just start  
exercise training.      
     The design of the current study filled the blank of the previous studies in sedentary 
subjects, since Thomas et al did not train subjects, and Warner et al did not measure PPL 
TG; while the current study did both.  The basic thought of the current study is that when 
sedentary people participate into exercise program, in time they will respond to fish oil 
supplementation and acute exercise (additive effect) in PPL TG just like trained subjects.  
But before they reach that point, there are questions need to be answered: 1) Is the 
recommendation of combining fish oil supplementation with exercise training valid in 
sedentary people? 2) How long does it take for this interference effect to convert to a 
beneficial combination in sedentary people who start exercise training?   
     The current study provided subjects n-3FA 4 g/day for 4 wk; about half of the subjects 
also took aerobic exercise training 5 d/wk.  Although there were no differences in FO 
group in PPL parameters pre vs. post treatment, there was a significant decrease in TG-
AUCT in two groups together after the treatment.  This might because the sample size of 
FO group was not great enough to bring a statistic change; while two groups together 
overcome this problem.  On the other hand, there were significantly lowered TG values in 
several time points in each group and two groups together in post treatment PPL trails, in 
the current study (Table 5, Figure 3, Figure 4).  These results indicated 4 wk fish oil 
supplementation attenuated PPL TG.  Thomas et al (85) provided subjects fish oil 
supplement for 3 wk at the same dose, but they did not found statistical change in PPL 
parameters; they also did not find TG values decreased significantly in the time points 
other than 0h.  This might because in the current study treated subjects with fish oil 
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supplement for 4 wk, while Thomas et al only did for 3 wk.  We analyzed the 3 day diet 
log and found the intake of n-3 FA was insufficient in the subjects; the average amount 
was 0.25 g/day.  According to the recommendation of American Heart Association, 
EPA+DHA 0.5 to 1.8 g/day, there might be n-3 FA deficiency in the subjects before the 
study started.  If that was the case, it may take shorter time for people who do not have n-
3 FA deficiency to react to fish oil supplementation in PPL TG, than the subjects of the 
current study.  
     Exercise training did provide some additive effects in attenuating PPL TG, as in 
FO+ExTr group, there were significant changes in TG-AUCT and TG-PeakT after the 
treatment, in Ex-PPL (Table 4, wk 0 vs. wk 4, Figure 7, Figure 8).  There was no change 
in PPL parameters in FO group, although during the comparison of TG AUCT pre vs 
post, p= 0.077 showed the trend of decrease after treatment.  Combination treatment also 
decreased PPL TG values in more time points than FO alone, in Ex-PPL trial (Table 5).  
In FO group, TG values decreased only at 2 time points after treatment, although there 
was a trend of decrease in 2 other time points after treatment.  Although there were no 
differences between the two groups after 4 wk treatment, it is very possible that by 
extending exercise training period, sedentary subjects would gradually experience 
additive effect of the combination treatment in Ex-PPL TG, as observed by Smith et al 
(79). 
     Based on the results of the current study, the answers to the previous two questions 
would be: 1) The recommendation of combing fish oil supplementation with exercise 
training should be avoided in the first a few weeks of therapy, in sedentary people.  2) 
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There is evidence that the interference effect starts to convert into beneficial effect four 
weeks after sedentary people start exercise training program. 
Exercise and PPL 
     Many studies have indicated that exercise attenuates PPL TG (88, 97, 98).  
Surprisingly exercise 12h before high fat meal did not attenuate PPL TG in either 
treatment group in the current study (Table 3, Table 4).  However, the exercise bout was 
carried out by every subject in the lab under supervision.   
     One of the possibilities could be the diet of the subjects on the day before the fat 
loading test provided varied fat and/or calorie intake between PPL and Ex-PPL trials.  
Although we had instructed subjects to follow the same diet they took the day before the 
first PPL, in all the PPL trials afterward, it was still hard to confirm that they followed the 
instruction.  This dietary factor may contribute to the fact that there was no significant 
difference of TG values in 0h samples between PPL and Ex-PPL trials.  In fact 11 
subjects had their exercise fasting TG (0h sample in Ex-PPL) higher than non exercise 
fasting TG (0h sample in PPL) in pre testing; while this happened in 12 subjects in post 
testing.  This suggested the diet control was not sufficient.  In the future study, it would 
be ideal to provide a standard meal at least for the meal before fasting the day before the 
fat loading test.  This would minimize the impact of different diet on the baseline level of 
TG.   
     The second explanation was that the mode of exercise influenced results.  During pre 
testing, all the subjects did fast walking in the acute exercise bout; while in post testing, 5 
subjects from FO+ExTr group did slow jogging.  The target heart rate was 75% maxHR 
which was determined by VO2max test.  Although the target heart rate was the same with 
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the one used in the study of Zhang et al (97), their subjects did jogging instead of 
walking.  Thomas et al (85a) investigated energy expenditure in walking and jogging in 9 
young men.  They found at the same exercise heart rate, jogging caused higher energy 
expenditure and higher fat energy expenditure than walking.  This result indicated that 
different exercise mode had significant impact on fat utilization, which might influenced 
plasma TG level.  On the other hand, there have been several walking studies that had 
subjects expend between 800 and 1,000 kcal per exercise session (90, 91).  Despite the 
fact that they expended more kcal during their exercise session, the reduction in PPL was 
smaller when compared to the running trials (79, 97).  This also is the case with the 
cycling study (41).  During the 90 min bout of cycling, subjects expended 1,070 kcal of 
energy, and the reduction in PPL was less than the running studies (79, 97) and similar to 
the walking studies (90, 91).  Since exercise modes influence energy expenditure and fat 
metabolism, it is important to use jogging during the acute exercise in Ex-PPL study.  
     The primary difference between the modes of exercise is that the eccentric component 
of muscular contractions is much greater in running than in walking and cycling.  This 
eccentric component may alter fat metabolism.  Researchers have reported that fat energy 
expenditure was greater during jogging over a 60 min exercise session than cycling (86).  
It was concluded that this increase in fat energy expenditure was probably related to the 
eccentric component of the jogging.  Since the eccentric component of walking is less 
than jogging, it would be reasonable to assume that this would be the case if jogging were 
to be compared to walking.  Based on these findings, it seems that running is more 
effective in reducing PPL than walking and cycling when the activities are performed at 
the same intensity levels.  In the current study, 50% of the subjects in FO+ExTr group; or 
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25% of subjects in two groups together did slow jogging during post testing.  This 
percentage was not large enough to lead to a statistically significant change between PPL 
and Ex-PPL in post testing.  However, among the 5 subjects who jogged during post 
testing, 3 of them showed decreased TG-AUCT, TG-AUCI, TG-PeakT and TG-PeakI in 
acute exercise PPL, in comparing to non exercise PPL.  This indicated the mode of 
exercise did influence the results.  On the other hand, among these 5 subjects, 3 of them 
had higher 0h TG values in Ex-PPL trial than in PPL trial in post testing.  This again 
indicated the impact of diet on baseline (0h) TG values.             
     The third explanation is that in the current study, the exercise bout did not induce 
enough LPL change relative to the amount of fat intake.  Exercise has been shown to 
induce LPL gene expression in skeletal muscle (78).  LPL activity becomes elevated 
shortly after an exercise session, but the activity does not peak until 18h after an exercise 
session and remains elevated for up to 30h (44).  It is believed that the increased LPL 
activity in muscle may play the most important role in the attenuated TG response (51).  
Study has shown that exercise induces human LPL gene expression predominantly in 
skeletal muscles, and more vigorous skeletal muscle activity may result in greater 
increase in LPL production (78).  Because jogging involves more muscle activity than 
walking does, jogging may induce grater LPL activity than walking does.  Zhang et al 
(97) found TG AUC was 51% lower in Ex-PPL in comparing with PPL; and Smith et al 
(79) found a 50% decrease in TG peak response in Ex-PPL.  Since these two studies all 
used jogging during acute exercise, it is very possible that the exercise in the current 
study might not be intensive enough to induce great LPL release.  Since the current study 
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did not measure the LPLa pre and post treatment, there was no direct evidence to prove 
this explanation.  
     Smith et al (79) measured LPLa in recreational trained subjects during PPL and Ex-
PPL trial.  They found although TG-AUCI during Ex-PPL trial was 40% less than the 
TG-AUCI during the PPL trial, there were no statistically significant differences between 
the LPLa for these two trials.  This result suggested the change of PPL TG was not 
parallel to that of LPLa.  It begged the question, if there is anything to do with the source 
of LPLa.  If adipose tissue is the primary source of LPLa during the PPL trial, maybe 
exercise increased muscle LPLa which hydrolyzed TG at the greater rate than LPLa in 
adipose tissue during Ex-PPL trial.  If this is the case, it is easy to think that in the current 
study, exercise did not induce enough LPLa change in skeletal muscle as it was in other 
studies.  Again it may due to the mode or intensity of the exercise.  It would be useful if 
tissue samples were taken to measure the LPLa activity in adipose tissue and skeletal 
muscle in the future study. 
     The fourth reason may be due to the variability associated with the PPL responses.  
There were 6 subjects who had TG peak response less than 50 mg/dl; and 2 subjects who 
had TG peak response greater than 150 mg/dl in PPL trial during pre testing in the current 
study.  After 4 wk treatment, there were 3 subjects who had TG peak response less than 
50 mg/dl; and 4 subjects had TG peak response greater than 150 mg/dl during post 
testing.  This range of responses resulted in large amount of variability in TG values and 
in any variable that was calculated from these values.  The interesting phenomenon was 
the number of subjects, who had TG peak response lower than 50 mg/dl or higher than 
150 mg/dl, decreased after 4 wk of treatment.  It seems fish oil supplementation 
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normalized the response to high fat meal.  This may due to the positive impact that fish 
oil has in fat metabolism.              
     Although single bout of exercise before fat loading did not decrease PPL TG, exercise 
training for 4 wk did provide a lower TG-AUCT and TG-PeakT in FO+ExTr group in 
comparing with before treatment in Ex-PPL trials.  On the other hand, among the four 
subjects who had TG peak response greater than 150 mg/dl in post testing, three of them 
were from FO+ExTr group.  This suggested the combination treatment group had better 
response to acute exercise in PPL.  This result agreed with other studies (79, 98).  In 
recreational trained subjects in the study of Smith et al, fish oil supplementation in 
combination with acute exercise, PPL parameters were significantly lower than fish oil 
alone.  Ziogas et al (98) investigated PPL TG in sedentary, recreational trained, and 
endurance trained subjects.  They found recreational trained, and endurance trained 
subjects, TG-AUCT was significantly lower than sedentary subjects.  These results 
indicated that exercise training attenuates PPL TG; exercise training induced greater 
response in acute exercise PPL.  Studies have found exercise training increases LPLa, but 
this increase was transient (77, 78).  If exercise training induced LPLa could not be 
accumulated, there would not be difference between sedentary and trained subjects in 
acute exercise PPL, after trained subjects stopped exercise training for a day or two.  But 
that was not the case in the study of Ziogas et al (98); their subjects did not participate 
into vigorous exercise 36h prior PPL test.  The most recent study by Pilegaard et al (75) 
suggested that the cumulative effects of transient increases in transcription during 
recovery from consecutive bouts of exercise may represent the underlying kinetic basis 
for the cellular adaptations associated with exercise training.  If this is true, it may 
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explain why subjects in the study of Smith et al responded to acute exercise PPL better 
than those in the current study.  Since the subjects in the study of Smith et al (79) 
participated in daily physical activities longer than those in the current study.   
     Since both n-3FA and exercise training increase LPL, it is reasonable that the two 
methods in combination would provide an even better result in attenuating PPL TG.  
However, it remains unclear why acute exercise causes interference in the effect of fish 
oil in attenuating PPL TG, in sedentary subjects.  The mechanism of how exercise 
training interacts with fish oil supplementation to improve the response of human subject 
to acute exercise in PPL has yet to be discovered too.   
Fish oil and PPL   
     Researches have found n-3FA supplementation reduce PPL TG (37, 79, 85, 94).  The 
reduction in PPL following n-3FA supplementation is hypothesized to be due to 
decreased hepatic TG secretion (very low-density lipoprotein, VLDL) and/or decreased 
intestinal TG secretion (chylomicrons and VLDL) (38).  This inhibition of TG secretion 
reduces the amount of TG that is present in the plasma, thus lowering PPL.  In the current 
study, there were significant changes in TG-AUCT in two groups together after the 
treatment, in PPL trial.  There were significant changes in TG-AUCT and TG-PeakT in 
two groups together after the treatment, in Ex-PPL trial.  This result agreed with previous 
studies that fish oil supplementation attenuates PPL TG.  Despite of the significant 
changes in two groups together, there was no change in FO group.  This might because 
the sample size in FO group was not large enough (n=10), but when two groups were 
combined, the sample size increased (n=20), the changes became significant.     
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     While postprandial lipemia is one of the most accurate predictors of CVD risk, fasting 
TG remain to be a valuable parameter.  In the current study, both groups had decreased 
TG in fasting samples and acute exercise sample (12h after acute exercise) after the 
treatment.  However, there was no difference between the two groups in fasting TG after 
the treatment.  This result agreed with Warner et al (93) who found exercising 3 days/wk 
for 12 wk in conjunction with fish oil supplementation lowered fasting TG level.  
However, the response was the same in combination treatment group and fish oil only 
group.  In considering Warner trained the subject for 12 wk, which was 3 times longer 
than the current study, combination treatment might not attenuate fasting TG more than 
fish oil supplementation alone even in a long run.          
HDL and LDL 
     The effects of fish oil supplementation on HDL and LDL have not been consistent in 
previous studies (72, 81, 82).  Zhang et al has reported that acute exercise (exercise on 
treadmill for 1h at 60% VO2max) increases HDL-C (97), which was not the case in this 
study.  However, acute exercise 12 h before blood sampling did increase HDL2-C and 
decrease HDL3-C in two groups together in this study.  As previously discussed, the 
intensity of walking and jogging is very different; it is possible that the intensity of the 
acute exercise in the current study was too low to induce HDL-C change.  It is also 
possible that different modes of exercise influenced HDL-C differently, since Zhang et al 
(97) used jogging, while most of the subjects in the current study did walking.     
     This study found increased HDL-C and HDL2-C and decreased of HDL3-C in 
FO+ExTr group after the treatment.  There was an increase of HDL2-C, but HDL-C and 
HDL3-C were unchanged in FO group.  This result suggested that both treatment groups 
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had improved HDL profile, while the improvement in combination treatment group 
seems to be more ideal.  Other investigators have reported that n-3 FA supplementation 
does not affect baseline HDL-C (28, 85).  This was confirmed in the current study.  There 
was no difference between FO and FO+ExTr group in HDL-C and subfractions after the 
treatment.  Acute exercise combined with fish oil supplementation (85), or exercise 
training combined with fish oil supplementation (current study and Warner et al) all did 
not showed additive effects for HDL-C or subfractions in sedentary people.  This seems 
to be true in active people (79).   
     There were several possibilities why a larger increase in HDL cholesterol did not 
occur in the exercise group.  First, the intensity of exercise may have been too low.  
Because the combination treatment group showed significant improvement of VO2max 
and the subjects were working at 75% maximal HR, it is unlikely that intensity was too 
low to effectively increase HDL-C.  Second, the frequency or duration of exercise 
training may not have been sufficient.  Warner et al trained subject 3 d/wk for 12 wk still 
did not improve HDL-C, while another study which used the same training protocol 
successfully induced HDL-C change (43).  The exercise training was more frequent than 
Warner et al.  It is possible that after a longer period of time (8-12 wk), HDL-C change 
would be induced.  Finally one could not rule out the possibility that fish oil and exercise 
interacted and affected the mechanism of HDL-C production and removal.               
     It has been a concern about prescribing n-3 FA due to the potential to elevate LDL-C 
(20, 61).  Fish oil did not significantly increase LDL-C concentration in the current study.  
On the other hand, Warner et al (93) has concluded that aerobic exercise significantly 
adds to the hypolipidemic effects of fish oil by causing a decrease in LDL-C and by 
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improving the composition of LDL.  The current study did not find a decrease of LDL-C 
in any treatment group.  This may because of the exercise training duration of the current 
study was shorter than that of Warner.   
     Since we did not measure the concentration of some important enzymes in lipoprotein 
metabolism, like LPL, lecithin cholesterol acyltransferase (LCAT), and cholesterol ester 
transfer protein (CETP), it would be difficult to analyze more detailed metabolic change.  
CETP catalyzes the exchange of TG from TG-rich lipoproteins with cholesterol from 
HDL, especially HDL2-C.  Elevated activity of this enzyme may increase CVD because 
of the potential for lowering HDL-C and HDL2-C.  CETP has been shown to be 
decreased by exercise training, but Zhang et al (96) found no change of this enzyme 
activity over 24 h following a single aerobic exercise session.  LCAT binds CEs to HDL, 
which may enhance cholesterol uptake from tissues.  Exercise has been shown to 
stimulate the activity of this enzyme, but the results have not been consistent (26, 96).  
Thomas et al (87) reported LCAT and CETP functions were not stimulated by fish oil 
supplementation and exercise. 
Inflammatory markers 
     Hypertriglyceridemia-induced endothelial cell dysfunction plays a critical role in the 
pathology of atherosclerosis.  Many researches have supported fatty acid-mediated 
endothelial activation and dysfunction as a consequence of hypertriglyceridemia (10, 32).  
Hypertriglyceridemia leads to high plasma concentration of low-density lipoprotein 
cholesterol (LDL-C), and low plasma concentration of high-density lipoprotein 
cholesterol (HDL-C).  It has been shown that plasma concentration of TG, and ratios of 
TC/HDL-C, LDL-C/HDL-C were positively correlated to CRP (63, 95).  Plasma 
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concentration of HDL-C was shown to be negatively correlated to CRP (27).  
Hypertriglyceridemia is also found to be correlated to cell adhesion molecules, thus 
contributing to inflammatory procedure and atherosclerosis (45). 
     Researches have found that fish oil decreases the concentrations of inflammatory 
markers in the blood; thus it is believed fish oil has anti-inflammatory effect (19, 24).  
There were studies reported that fish oil intake decreased IL-6 level (19, 22).  Researches 
by Eschen and Miles (30, 60) suggest the impact of fish oil supplementation on sICAM-1 
varied with dose of supplement as well as age and gender of subjects.  On the other hand, 
it is also believed that exercise training inhibits inflammatory process and thus reduces 
the risk of lifestyle related diseases (57).  Acute exercise however, has been proved to 
induce inflammation (59, 80).     
     Based on these understandings, the current study tried to investigate if fish oil has 
inhibitory effects on acute exercise induced inflammation.  Similar method has been used 
by Phillips et al (74) on a dietary supplement study, during which they successfully 
induced CRP and IL-6 by eccentric exercise.  In the current study, CRP and IL-6 were 
measured in exercise samples (12h after acute exercise), while CRP was also measured in 
fasting samples pre and post treatment.  Since previous studies have conflict results on 
sICAM-1 concentration changes after acute exercise (58, 62, 64), the current study only 
measure the sICAM-1 concentration on fasting samples pre and post treatment.  In the 
current study, since acute exercise was not sufficient to cause inflammation, the ability of 
fish oil to attenuate inflammation induced by exercise could not be investigated.         
CRP 
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     CRP is an acute phase inflammatory protein that is released in response to acute 
injury, infection, or other inflammatory stimuli.  There was no significant change of CRP 
after the treatment in fasting samples in both groups in this study.  This suggested neither 
fish oil, nor exercise training attenuated CRP level in sedentary subjects after 4 wk 
treatment.  On the other hand, CRP values in exercise samples were not different from 
the non exercise samples pre treatment.  This indicated acute exercise had no significant 
impact on CRP values in this study.  Since acute exercise did not successfully stimulate 
CRP, it is impossible to investigate whether fish oil and exercise training attenuated CRP 
reaction after acute exercise in this study.   
     There were studies showed CRP levels after exercise correlated to the muscle damage 
level (5, 73).  Paulsen et al (73) measured maximal force-generating capacity, creatine 
kinase (CK), CRP, and IL-6 in 11 healthy men before and after 300 maximal eccentric 
actions with m. quadriceps.  They found a positive correlation between acute loss of force 
and changes in CK, and between the acute loss of force and changes in CRP.  If that was 
the case in the current study, it would be easy to explain the negative response of CRP 
after the exercise session, since the intensity of the exercise may not be enough to induce 
CRP change.   
    However, there is also a possibility that the time of sampling was impropriate to detect 
the CRP change.  Some studies showed CRP peaked a day after the exercise bout (59, 
33), Paulsen et al (73) reported CRP peaked 2 days after exercise.  Byrne et al (17) had 
subjects performed military exercise, prolonged moderate physical exertion in full 
battledress, covering approximately 10 miles.  They reported no change of CRP 
concentration 12h after exercise.  The more reasonable analysis is that the exercise bout 
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in the current study did not induce detectable CRP change at 12h.  If the intensity was 
higher, it would be possible to see an increase of CRP concentration at 12h if not peaked.    
     Among these studies which investigated how exercise affected CRP; there was a large 
variety of mode and intensity of exercise, including military exercise (17), bench stepping 
(33), cycling (59), and maximal eccentric action of a certain muscle (73).  This could be 
one of the possibilities which caused different results, since as previous discussed, 
different modes and intensity of exercise affect energy expenditure, fat metabolism and 
muscle damage differently.  This may have indirect impact on CRP concentration after 
exercise, and also make it hard to compare the results among studies.          
     Although fish oil has been associated with anti-inflammatory effect, evidence 
regarding the effects of omega-3 fatty acids on hs-CRP is inconclusive (18, 29, 53, 54).  
In terms of the impact of DHA on acute phase proteins, published results range from no 
effect to a lowering effect on CRP levels (29, 54).  The difference in study populations, 
particularly from an age and health standpoint, may account for the differences observed 
in these studies.              
     There has been argument about how much change of CRP value indicates the 
inflammatory change of the body.  Kushner et al (48) believed researchers should be 
cautious when explain the CRP values between 3 and 10 mg/L.  It may only imply a mild 
degree of tissue stress or injury, suggesting the presence of distressed cells, rather than a 
resulting inflammatory response.  If this is true, exercise induced CRP has to reach a 
certain level before one could interpret it as a systemic inflammatory response.  This will 
increase the difficulties and intensities of exercise bouts.                 
IL-6  
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     IL-6 is the main stimulant for the hepatic production of CRP.  Researchers have 
indicated that IL-6 also predict future cardiovascular events (76).  Elevated IL-6 levels 
amongst patients presenting with acute coronary syndromes were a strong independent 
predictor of increased mortality (50).     
     Investigators have pointed out that IL-6 is the central mediator of exercise 
immunology (66, 67).  It has been found that plasma IL-6 starts to increase within the 
first hour of prolonged exercise and continues to rise depending on the duration of 
exercise (65, 70).  On the other hand, other studies have indicated that shorter intensive or 
mild prolonged exercise of less than 1h seems to be insufficient to significantly alter 
plasma IL-6 concentration (14, 25).  There has been research indicated that IL-6 levels 
after exercise correlated to the muscle damage (15).  In the current study, IL-6 was not 
detectable in most of the samples 12 h after exercise, but was detectable in the 2h 
samples in Ex-PPL.  Based on the results of previous studies, it is more likely that the 
high fat meal stimulated IL-6 release in the current study.  Few studies reported high fat 
meal induced IL-6.  Corpeleijn et al (21) investigated IL-6 change at postprandial stage in 
male subjects with impaired glucose tolerance.  They found high-fat meal can evoke IL-6 
release from muscle.  However, it is unknown if this is the case in healthy people.  In the 
current study high fat meal successfully induced IL-6 in both pre and post treatment Ex-
PPL trials.  The future study may be able to investigate if fish oil supplement inhibits 
inflammation induced by high fat meal.  Although exercise and high fat meal both can 
induce inflammation, one should be cautious when combining these two factors in 
inflammatory study; since the combination effect of these two factors on inflammation 
has yet to be determined.  
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     Researches have found fish oil intake decreased IL-6 level (19, 22).  There was in 
vitro evidence that DHA reduced endothelial expression of IL-6 in stimulated cells (23, 
24).  De Caterina et al (24) used a variety of stimulating stressors to invoke an 
inflammatory response and observed a significant reduction in IL-6 levels in the presence 
of DHA.  Similarly, Phillips et al (74) used eccentric exercise to induce IL-6 and CRP, 
and found a dietary supplement mainly DHA attenuate the IL-6 and CRP in the subjects 
after exercise.  Based on the success of these studies, it seems to be a practical idea to 
magnify the inflammatory marker change by exercise or other methods, before 
investigating if a factor could decrease these markers.                   
sICAM-1 
     The pathology of atherosclerosis has been regarded to be an inflammatory procedure.  
One of the key initial events in the development of atherosclerosis is the adhesion of 
monocytes to endothelial cells, with subsequent transmigration into the vascular intima.  
Leukocyte and vascular adhesion molecules such as ICAM-1 play critical roles in the 
adhesion of monocytes to endothelial cells.  Research also has shown high blood TG is 
correlated to cell adhesion molecules, thus contributing to atherosclerosis (45).   
     The current study did not find sICAM-1 change after 4 wk treatment in either group.  
Studies in terms of exercise induced sICAM-1 have provided conflicting results.  Nielsen 
et al (64) used subjects who participated in marathon or half-marathon, and found 
increased sICAM-1 after both treatments.  Mizia-Stec et al (62) used patients with 
coronary artery disease to complete treadmill stress test, and found no change in sICAM-
1.  Meksawan et al (58) combined dietary fat intake with maximal exercise test.  They 
found subjects who had fat intake equaled to 19% total calories, which put them in 
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negative energy balance, resulted in increased sICAM-1.  Akimoto et al (5) had healthy 
male subjects to perform three different kind of exercise, bicycle ergometer at 80% 
VO2max for 16 min, 42 km endurance running, and 30-min downhill running at intensity 
of ventilation threshold.  They found plasma sICAM-1 concentration increased a day 
after the endurance running (12%) and downhill running (14%), but not after ergometer 
exercise.  Plasma CRP and creatine kinase concentration also increased a day after 
running.  They concluded exercise associated with muscle damage and/or inflammation 
results in increased levels of plasma sICAM-1.  If this is the case, the current study might 
not provide sufficient muscle damage to induce sICAM-1, because of the mode of 
exercise, as previously discussed.    
     The impact of fish oil on plasma sICAM-1 concentration has been investigated by 
previous studies.  Lopez-Garcia et al (52) analyzed the dietary intake of 727 women, aged 
43 to 69 y.  They found CRP levels were 29% lower among those in the highest quintile 
of total n-3 fatty acids, compared with the lowest quintile; IL-6 levels were 23% lower, 
E-selectin levels 10% lower, sICAM-1 levels 7% lower, and sVCAM-1 levels 8% lower.  
Long-chain n-3 fatty acids (EPA and DHA) were inversely related to sICAM-1 and 
sVCAM-1.  However these associations were not modified by intake of vitamin E, 
dietary fiber, trans fatty acids, or by the use of postmenopausal hormone therapy.  Abe et 
al (1) treated hypertriglyceridemia patients with n-3 fatty acids 4g/d for at least 7 months, 
and found reduced sICAM-1, E-selectin and TG levels.  This result support previous in 
vitro data showing that disorders in triglyceride and HDL metabolism influence CAM 
expression and treatment with fish oils may alter vascular cell activation.   
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     However, it seems the effect of n-3 FA on sICAM-1 is complex and may depend on 
gender and dose.  Eschen et al (30) performed a double blind study with 60 healthy 
subjects.  Subjects were randomly assigned to receive a daily supplement of n-3 FA 6.6 g, 
n-3 FA 2.0 g, or olive oil for 12 weeks.  Among the women, there was a significant 
decrease in sICAM-1 in the n-3 FA 2.0 g group and a significant increase in sVCAM-1 in 
the n-3 FA 6.6 g group.  In the men, after supplementation with 6.6 g of n-3 FA, there 
was a significant decrease only in sP-selectin.  The subjects in the current study received 
4.0 g n-3 FA daily for 4 weeks, and there were no significant changes in sICAM-1 
concentrations of all the subjects after the treatment.  When sICAM-1 concentrations of 
female subjects were processed by 2-way repeated measures ANOVA, there were no 
significant changes in FO vs. FO+ExTr and pre vs. post treatment.  This may because the 
dose and treatment length of n-3 FA supplementation in the current study were less than 
the study of Eschen et al.  
Plasma Volume Change 
     Investigators have indicated that plasma volume (PV) is affected up to 24h after an 
acute bout of high-intensity or endurance exercise (89).  During exercise, blood colloid 
osmotic pressure increases, and leads to the fluid goes towards interstitial spaces, thus 
decreases the PV.  A few hours after exercise, blood pressure decreases because of 
vasodilation; baroreceptor input decreases; antidiuretic hormone (ADH) secretion 
decreased; kidney reserves liquid, and thus increases plasma volume (34).  The PV 
change in the current study agreed with this theory.  By measuring Hct in blood samples 
at Ex-PPL 0h which was 12h after acute exercise, we found a decreased PV, the average 
change of PV was -4.1 ± 1.3% in comparing to pre exercise.  When Ex-PPL 0h TG 
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values were corrected according to this PV change, the statistic results of PPL TG 0h vs. 
Ex-PPL TG 0h remained to be the same.  At PPL 6h which was 18h after exercise, there 
was a significant increase of PV in terms of % change of PV, -0.6 ± 1.3%, between PPL 
6h and 0h samples.  When PPL TG values at 6h were corrected according to PV changes, 
the statistical results remained to be the same.      
Limitation to the study 
     The acute exercise session in Ex-PPL did not provide enough effect as it should.  As 
previously discussed, this mainly because of the walking mode may not have been 
sufficient.  The diet the day before PPL and Ex-PPL trials were not sufficiently 
controlled.  These two factors covered the effect of acute exercise on attenuating PPL-
TG.  The low intensity exercise may also responsible for the failure in inducing 
inflammatory markers, and HDL-C.  The small number of subjects, n=10 in each group 
in PPL TG study is a limitation to the study.  This small sample size along with the 
variability of PPL response reduced the statistical power of the result.  Inflammatory 
markers in more time points should be analyzed due to the different peaking time of these 
proteins after exercise.  On the other hand, if high fat meal induced IL-6, it might also 
induce other inflammatory markers in PPL trial.     
Summary of results        
     The current study found acute exercise did not attenuate PPL TG parameters, and TG 
values at any time points.  Fish oil supplement only and fish oil in combination with 
aerobic exercise training attenuated PPL TG.  Combination treatment had no interference 
on n-3FA in attenuating PPL TG in previously sedentary people after 4 wk treatment.  
Aerobic exercise training improved body composition and aerobic capacity of the 
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previous sedentary subjects.  Combination treatment provided more ideal HDL-C and 
subfraction change than fish oil only, although the difference between the two treatments 
was very mild.  Fish oil supplementation did not alter LDL-C in sedentary subjects.  
Exercise training at 60% VO2max for 60 min did not successfully induce inflammatory 
marker change, but high fat meal increased plasma IL-6 concentration.  Neither fish oil 
supplementation, nor combination treatments inhibit inflammation and cellular adhesion. 
Conclusions 
     N-3 FA supplementation attenuates PPL in sedentary subjects.  Exercise training has 
no interference or additive effects on n-3FA in attenuating PPL.  N-3FA does not 
attenuate inflammation; this may because our acute exercise did not induce inflammation.      
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                                 Dietary fat and inflammation 
     Life style related diseases have been the leading cause of death in industrialized 
nations.  The character of this life style is high energy intake and low energy 
consumption, which leads to a metabolic syndrome.  Dietary factors especially dietary fat 
intake has caught attentions in understanding of the impact of high energy intake on 
lifestyle diseases.  The Third Report of the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III focuses on therapeutic lifestyle changes as the 
cornerstone of therapy of CHD.  The components include reduced intakes of saturated fat 
and cholesterol, increased dietary fiber, inclusion of plant sterols/stanols, increased 
physical activity, and weight control (10).  Since inflammation is a key component of the 
metabolic syndrome, and has been shown to be involved in atherosclerosis, diabetes, 
cancer and other lifestyle diseases; it is necessary to discuss the relationship between 
dietary fat and inflammation. 
Saturated fatty acid and trans fatty acids induce inflammatory procedure 
     High fat diet always leads to positive energy intake, which causes obesity.  Obesity is 
highly correlated with inflammation with the fact that elevated CRP levels have been 
associated with obesity (52).  On the other hand, weight loss causes decreased CRP in 
obese subjects (17).  Animal study also indicated that many inflammatory and 
macrophage-specific genes are dramatically upregulated in white adipose tissue in 
obesity induced by high fat diet (55).  These results indicated the chronic effect of high 
fat diet characterized by high energy intake and obesity, leads to inflammation.   
     There have been several studies that reported a positive correlation between diets with 
a high content of saturated and trans fatty acids (TFAs) and biomarkers of inflammation.  
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King et al (20) examined the National Health and Nutrition Examination survey data 
from 1999 to 2000; and revealed a modest association between saturated fat consumption 
and elevated CRP.  Analysis of data from the Nurses’ Health Study I cohort revealed a 
73% higher level of CRP in women in the highest quintile of TFAs intake compared with 
the lowest quintile (26).  TFAs intake was positively related to plasma concentration of 
CRP, soluble tumor necrosis factor receptor (TNFR2), E-selectin, sICAM-1, and 
sVCAM-1 in linear regression models after controlling for age, BMI, physical activity, 
intake of saturated fatty acids et al (27).  These large sample studies indicated saturated 
fatty acids and TFAs induce inflammatory procedure. 
     According to previous studies, there are two mechanism of TFAs affects 
inflammation.  First, TFAs has negative impact on lipoprotein profile, and the impaired 
lipoprotein metabolism induces inflammation.  Numerous studies have reported increases 
in triglyceride levels ranging from 1.0 to 24 mg/dl, with an average increase of 3.0 mg/dl 
per 2 percent of energy intake from TFAs (25, 46, 58).  Human study also indicated that 
TFAs diet not only increase LDL-C but also decrease HDL-C level (31, 58).  Impaired 
lipoprotein metabolism induces inflammation.  It has been shown that plasma 
concentration of TG, and ratios of TC/HDL-C, LDL-C/HDL-C were positively correlated 
to CRP (34, 57).  Plasma concentration of HDL-C was shown to be negatively correlated 
to CRP (9).  Studies have found that hypertriglyceridemia actived leukocytes, in vivo 
(38).  Since activation of leukocytes is obligatory for inflammation and atherogenesis by 
adhering to the endothelium via specific ligands, hypertiglyceridemia thus induces 
adhesion.  On the other hand, hypertriglyceridemia was found to be correlated to cell 
adhesion molecules, thus contributing to inflammatory procedure and atherosclerosis 
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(19).  LDL-C is a major cause of injury to the endothelium and underlying smooth 
muscle (12, 32, 33).  When LDL particles become trapped in an artery, they can undergo 
progressive oxidation and be internalized by macrophages by means of the scavenger 
receptors on the surfaces of these cells (12, 22, 32, 33).  The internalization leads to the 
formation of lipid peroxides and facilitates the accumulation of cholesterol esters, 
resulting in the formation of foam cells.  Since hypertriglyceridemia and increased LDL-
C play such important roles in inflammation and atherosclerosis, TFAs thus indirectly 
induces inflammation.    
     Second, there was evidence showed TFAs related to endothelial dysfunction (6, 26), 
but the biological mechanisms underlying the adverse effects of TFAs on endothelial 
function are not clear.  TFAs are incorporated into endothelial cell membranes and thus 
could alter cellular and macromolecular components acting at the interface of the blood 
vessel wall.  This could result in changes in the antihemostatic properties, altered 
vascular tone, hyperadhesiveness to blood leukocytes, and increased cytokine and growth 
factor production, all of which are characteristics of endothelial dysfunction (6).    
Hypertriglycerdemia leads to endothelial cell dysfunction 
     High fat diet is directly related with postprandial triglyceridemis.  Chronic 
hypertriglyceridemia or postprandial triglyceridemia, elevated levels of triglyceride-rich 
lipoproteins, including chylomicrons, very low density lipoproteins (VLDL) and their 
remnants, are an independent risk factor in the development and progression of 
atherosclerosis.  Hypertriglyceridemia, particularly when associated with decreased HDL 
and abdominal or visceral obesity, is a highly atherogenic phenotype (24).          
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     There is evidence that hypertriglyceridemia-induced endothelial cell dysfunction plays 
a critical role in the pathology of atherosclerosis, and researches have detected the 
following mechanisms for this procedure.  First, hypertriglyceridemia can lead to 
endothelia cell dysfunction associated with increased vascular superoxide anion 
production and a subsequent decrease in nitric oxide bioavailability (23).  Second, it has 
been reported that leukocyte, and especially monocyte, adhesion to the endothelial 
surface is stimulated by triglyceride-rich lipoproteins (4, 7).  Third, endothelial 
dysfunction was observed after consuming a high-fat meal and is associated with 
augmented oxidative stress manifested by the depletion of serum antioxidant enzymes 
and increased excretion of oxidative modification products (48).  Research has indicated 
that endothelia cell activation during metabolic states of hypertriglyceridemia and PPL is 
redox sensitive (8).  Doi et al reported that a-tocopherol or N-acetylcysteine can suppress 
endothelia expression of ICAM-1, VCAM-1 and tissue factor, mediated by remnant-like 
lipoprotein particles isolated from plasma of hyerptriblyceridemic patients.   
     Fourth, high LPL activity is associated with endothelial cell dysfunction and 
atherosclerosis.  In atherosclerosis, LPL is overexpressed in vascular lesions and also 
produced by monocytes, marcrophages and smooth muscle cells (37, 43, 56).  It was 
shown in both cultured human umbilical vein and human coronary artery endothelial cells 
that inflammatory cytokines which are implicated in the etiology of vascular diseases, 
such as TNF-alpha and IL-1 beta, could upregulate endothelial cell-derived LPL mRNA 
(15).  These results indicated that high LPL activity related with inflammation may play a 
critical role in the pathology of atherosclerosis.  Furthermore, Chung et al (3) found that 
lipoprotein remnants derived from human triglyceride-rich lipoproteins produced after a 
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meal rich in polyunsaturated fat were more injurious to cultured vascular endothelial cells 
than those produced after a meal rich in saturated fat.  These data support the hypothesis 
that PPL hypertriglyceridemia and the simultaneous release of free fatty acids during 
LPL-mediated TG hydrolysis in the proximity of the endothelium can cause endothelial 
cell injury.  
N-3 fatty acids and inflammation 
     Epidemiological studies showed an inverse correlation between dietary fish or fish oil 
consumption and biomarkers of inflammation (28), although the results from intervention 
trials have not yet confirmed.  The mechanism of the anti-atherosclerosis effect of N-3 
fatty acids has been investigated by many laboratories.  The research group of De 
Caterina et al (29) investigated the intracellular generation of reactive oxygen species 
(ROS) in endothelial cells treated with various fatty acids.  It is believed that ROS, 
generated in low concentrations, may function intracellularly as second messengers in 
mediating the activation of NF-κB and activator protein 1.  De Caterina et al (6) 
stimulated endothelial cells with cytokines or lipopolysaccharide.  Preincubation of 
endothelial cells with the DHA blunted the endothelial response to the proinflammatory 
stimulation in terms of VCAM-1 surface expression or the release of macrophage colony 
stimulating factor.  Such effects were accompanied by a decreased production of ROS 
and a sparing in the depletion of the intercellular antioxidant reduced glutathione.  These 
results indicated that n-3 fatty acids may exert a direct vascular atheroprotective effect by 
inhibiting endotherlial activation through a quenching of stimuli-induced increase of 
ROS.   
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     The second possible mechanism is that EPA and DHA alter the metabolism of 
adhesion molecules such as VCAM-1, E-selectin, and ICAM-1.  Abe et al (1) reported a 
9% reductionin sICAM-1 and a 16% reduction in sE-selectin, in hypertriglyceridemic 
subjects receiving 3.4 g/d of high purified n-3 fatty acid ethyl esters for 7 to 12 months.  
There is also in vitro evidence that DHA reduces endothelial expression of VCAM-1, E-
selectin, ICAM-1, IL-6 and IL-8 in stimulated cells (5, 6).  These results were confirmed 
by studies in smokers and in coronary patients (18, 41). 
     The third potential anti-atherogenic mechanism of n-3 fatty acids is their interference 
with the arachidonic acid cascade.  EPA not only can replace arachidonic acid in 
phospholipids bilayers, but it is also a competitive inhibitor of cyclooxygenase, reducing 
the production of prostaglandins and thromboxanes (49).  EPA and DHA can inhibit 
platelet affregaton by reducing the affinity of platelet TxA2/PGH2 receptor for its ligand 
(2).   
     Although there are a lot of intervention studies about n-3 fatty acids influences on 
inflammation, the results have been conflicting.  The reason for this is that there are a lot 
of differences among the studies, the dose of n-3 fatty acids, and the duration of 
treatment; the character of the subject population, the standard and method of evaluation, 
the existent of other therapy, et al.  Among these factors, the quality and stability of n-3 
fatty acids preparation has not been widely known until recently.  Highly concentrated 
fish oils usually have markedly lower stability than natural fish oils.  It has been shown 
that intake of highly concentrated n-3 fatty acids preparations can have adverse effects 
(14, 44).  The adverse effects were ascribed to increased lipid peroxidation in the 
  
 
77
subjects.  Based on these understandings, one need to be cautious, and take all the relative 
factors into consideration, when comparing different results of the studies.  
The prevention effect of physical exercise to inflammation      
     In order to prevent lifestyle related diseases, it is probably the most important strategy 
to maintain a healthy lifestyle.  Despite of controlling dietary factors which influence the 
energy intake, it is equally significant to maintain the energy output by doing physical 
exercise.  Physical activity is associated with a range of health benefits, and its absence 
can have harmful effects on health and well being, increasing the risk for coronary heart 
disease, diabetes, certain cancers, obesity, and hypertension (50).  In fact exercise 
training plays such an important role that it is recommended by many institutes including 
Centers for Disease Control and Prevention (CDC), and American College of Sports 
Medicine (ACSM) to the general population to have a beneficial effect on their health 
(39).  
     Studies have reported exercise training decreased inflammation in both healthy and 
high risk subjects (13, 30, 51, 53).  Postmenopausal women, senior citizen and CVD 
patients are three important groups of people who have high risk of atherosclerosis.  
Studies (13, 51, 53) in these populations indicated exercise decrease the level of blood 
inflammatory markers, thus benefit prevention of atherosclerosis.  On the other hand, 
different types of exercise have been investigated in influencing inflammatory markers.  
King et al (21) analyzed the adults, age 17 and over who participated in the National 
Health and Nutrition Examination Survey (NHANES) III, total of 4072 people.  They 
found a significant lower likelihood of elevated inflammatory markers among regular 
participants in jogging, swimming, cycling, and aerobic dancing.  A nine-month 
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marathon training in 14 subjects also inhibited CRP (30).  Based on these studies, aerobic 
training decrease levels of the inflammatory marker, so that benefits the prevention of 
atherosclerosis.  The results of how resistance training influences inflammatory markers 
were inconsistent (11, 36, 42), thus the mode, intensity, and duration of resistance 
training in inhibiting inflammation has yet to be determined.  Despite of the effect of 
exercise in inhibiting inflammation, exercise training was also proved to improve 
endothelial function, by both animal and human studies (45, 54).   
     Scientists have tried to explain why acute exercise stimulates inflammation, while 
long term exercise training suppresses inflammatory process; although the mechanism 
remains to be unclear.  Physiologic study (40) has demonstrated that contracting skeletal 
muscle acutely produced IL-6, a cytokine that has dual functions in inflammation.  
Increased levels of inflammatory markers also have been demonstrated in the blood 
stream acutely after weight lifting and marathon running (35, 47).  While some scientists 
thought this elevation is due to muscle damage during exercise (42), some evidence 
showed different possibilities, as cytokine levels did not correlate with parameters of 
muscle damage, such as release of creatine kinase (16).  It may be due to intense exercise 
or a substantial mechanical load on the muscle.  Regular exercise training appears to 
modify this response, possibly due to a training effect, as CRP level actually decreased 
with regular endurance training (30).  More research needs to be conducted in this area.          
     Generally speaking, it is clear that in order to decrease the risk of life style related 
diseases; one should control diet, especially dietary fat intake, and to participate adequate 
amount of physical exercise.  This could help to inhibit pathology procedure of 
inflammation, and ultimately prevent people from lifestyle related diseases.       
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CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY 
Tom R. Thomas, Ph.D. 
Project # 1049539 
 
FOR HS IRB USE ONLY 
APPROVED  
 
 
___________________________________________
____ 
HS IRB Authorized Representative                          
Date 
 
EXPIRATION DATE:   
__________________________ 
 
 
 
STUDY TITLE: EFFECTS OF EXERCISE TRAINING PLUS OMEGA 3 FATTY ACIDS ON FAT 
HANDLING AND INFLAMMATION  
 
INTRODUCTION 
This consent may contain words that you do not understand.  Please ask the investigator 
or the study staff to explain any words or information that you do not clearly understand. 
This is a research study.  Research studies include only people who choose to 
participate.  As a study participant you have the right to know about the procedures 
that will be used in this research study so that you can make the decision whether or 
not to participate.  The information presented here is simply an effort to make you 
better informed so that you may give or withhold your consent to participate in this 
research study.   
Please take your time to make your decision and discuss it with your family and friends. 
 
You are being asked to take part in this study because you are an untrained person who 
may benefit from initiating an exercise program. 
 
This study is being sponsored by the Department of Nutritional Sciences and the Exercise 
Physiology Laboratory. 
 
In order to participate in this study, it will be necessary to give your written consent. 
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WHY IS THIS STUDY BEING DONE? 
Both long-term exercise and fish oil (omega-3 fatty acids) supplementation may be prescribed 
to help reduce blood fats after a meal (postprandial lipemia) and chronic inflammation.  It may 
be best to supplement with fish oil prior to starting an exercise program so that inflammation 
will be reduced.   The purpose of this research is to examine the interaction between exercise 
and fish oil intake on blood parameters related to the risk of cardiovascular disease.  
Specifically, we will explore the effect of exercise and fish oil intake on blood fats and/or 
markers of inflammation. 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
About 50 people will take part in this study at this institution.   
 
WHAT IS INVOLVED IN THE STUDY? 
If you volunteer, your participation will consist of the following: 
1. You will complete an initial screening consisting of the following: medical, diet, 
activity, bleeding disorders, and menstrual cycle (females only) questionnaires, a 
vigorous treadmill test to determine maximal oxygen consumption, and have your 
body composition (% fat) determined by skinfold measurements. 
2. You will record your food intake for three days and follow a 24-hour prescribed diet, 
including a 12-hour fast prior to the pre and posttesting sessions. 
3. You will complete four fat load trials, two before and two after the treatment.  During 
each trial, you will eat a high fat meal.  The high fat meal will consist of a milk shake 
that is based on your body weight and is made of ice cream and heavy whipping 
cream.  A 60 minute treadmill brisk walk/jog of moderate intensity will be included 
with two of the four trials.  The walk/jog will take place in the laboratory.  
4. You will have about 120 ml of blood withdrawn during each trial from a vein in your 
arm.  This is less than the 450 ml of blood collected when you donate blood. During 
each trial, you will be required to return to the lab 5-6 times in an eight hour period to 
have 10-40 ml of blood drawn each time.  These visits will last approximately 15 
minutes.  Each trial will be separated by 1-4 weeks.  The total number of visits to the 
lab is 28 for the fish oil only group and 48 for the fish oil plus exercise group.  The 
total amount of time in the lab for all trials is about 10 hours for the fish oil group and 
about 30 hours for the fish oil plus exercise group. 
5. Treatment:  You will ingest fish oil supplements (gel tabs, 4g/day) each day for four 
consecutive weeks.  Half the subjects also will exercise on a treadmill at moderate 
intensity (brisk walk or slow jog) for 45 minutes, 5 days per week for 4 weeks.  You 
will need to come to the lab each week to pick up the fish oil gel tabs.  For the 
exercise group, the total amount of time for exercise over 4 weeks is about 20 hours. 
6. You will not receive any placebos, and you will act as your own control. 
7. You will not change your exercise or activity other than what the research requires, 
and you otherwise will attempt to maintain the level of activity you had before you 
began the study.   
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8. Blood will be kept in storage until all tests have been run in case of errors in the lab 
testing process.  Once tests are completed, blood will be discarded. 
 
HOW LONG WILL I BE IN THE STUDY? 
If you volunteer, your participation will last 7-9 weeks, but it will be ended at any time at 
your request, and Dr. Thomas may end it at any time that, if in his judgment, it is in your 
best interest to do so.  Depending on the group in which you are assigned, your time 
commitment should be less than 30 hours.   
 
The investigator and/or your doctor may decide to take you off this study if the fish oil 
tablets cause nausea or other discomfort.  
 
If you are a woman and become pregnant, you also will be removed from the study. 
 
WHAT ARE THE RISKS OF THE STUDY? 
While in the study, you are at risk for the side effects described below.  You should 
discuss these with the investigator and/or your doctor.  There may be other side effects 
that we cannot predict.    
 
1. Potential lightheadedness and tiredness at the end of the exercise test to voluntary 
exhaustion.  This also could occur during the submaximal exercise sessions. 
2. Heart problems may occur during the exhaustive exercise test or the exercise training 
sessions. These potential problems include irregular heart beats and chest pain. In the 
event you experience any heart problems, we will stop the exercise session 
immediately and evaluate you to determine if you need medical attention. 
3. You may experience muscle soreness from the exercise. 
4. Temporary increases in low density lipoprotein (LDL) cholesterol levels may occur 
due to the fish oil supplements in subjects with high triglyceride levels.  This risk is 
temporary, but elevated LDL levels are associated with increased risk of heart 
disease. 
5. You may experience temporary discomfort and bruising where a needle is inserted to 
collect blood. 
6. Mild nausea may be caused by the fish oil supplements. 
7. As is true of all medications and medical treatment, there is always the possibility of a 
new or unexpected risk. 
For reasons stated above we will observe you closely while giving you the treatment 
described. If you have any worrisome symptoms or symptoms that my associates and I 
have described to you, notify me immediately.  My telephone number is (573) 882-8191. 
 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
If you agree to take part in this study, there may or may not be direct medical 
benefit to you. 
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You may expect to benefit from taking part in this research to the extent that you are 
contributing to the medical knowledge.  Other benefits include: Fitness evaluation, 
dietary analysis, and plasma lipid profile. 
 
WHAT OTHER OPTIONS ARE THERE? 
An alternative to taking part in this research would be to not participate in this 
research. 
WHAT ABOUT CONFIDENTIALITY? 
Information produced by this study will be stored in the investigator’s file and identified 
by a code number only.  The code key connecting your name to specific information 
about you will be kept in a separate, secure location.  Information contained in your 
records may not be given to anyone unaffiliated with the study in a form that could 
identify you without your written consent, except as required by law.  If the investigator 
conducting this study is not your primary, or regular doctor, he must obtain your 
permission before contacting your regular doctor for information about your past medical 
history or to inform them that you are in this trial. 
Results of this research may be published and reports may be made to government 
agencies, funding agencies, manufacturers or scientific bodies, but you will not be 
identified in any such publication or report.  In addition, the Federal Food and 
Drug Administration, other government agencies, and the manufacturer of the 
drug(s) used in this study may inspect and copy your medical records that apply to 
this research.  In all cases, information about you will be treated confidentially.  
WHAT ARE THE COSTS? 
Examinations and tests for this research will be paid for by the Exercise Physiology 
Laboratory.  
 
WILL I BE PAID FOR PARTICIPATING IN THE STUDY? 
You will be compensated $50.00 for your participation. 
 
WHAT IF I AM INJURED? 
It is not the policy of the University of Missouri to compensate human subjects in the 
event the research results in injury.  The University of Missouri, in fulfilling its public 
responsibility, has provided medical, professional and general liability insurance 
coverage for any injury in the event such injury is caused by the negligence of the 
University of Missouri, its faculty and staff.  The University of Missouri also will 
provide, within the limitations of the laws of the State of Missouri, facilities and 
medical attention to subjects who suffer injuries while participating in the research 
projects of the University of Missouri.  In the event you have suffered injury as the 
result of participation in this research program, you are to contact the Risk 
Management Officer, telephone number (573) 882-1181, at the Health Sciences Center, 
who can review the matter and provide further information.  This statement is not to 
be construed as an admission of liability. 
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WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Participation in this study is voluntary.  If you do not volunteer or if your 
participation is ended for any reason, this will not affect any care or consideration 
to which you are entitled.  In addition, the investigator of this study may decide to end 
your participation in this study at any time after Dr. Thomas has explained the reasons for 
doing so and has helped arrange for your continued care by your own doctor, if needed.   
 
You will be informed of any significant new findings discovered during the course of this 
study that might influence your health, welfare, or willingness to continue participation in 
this study.  
 
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
Please ask any questions you have about this research or how it will affect you, and I will 
answer them.  In addition, if you have any questions during your participation I, or one of 
my associates, will be glad to discuss them with you.  You may call me at (573) 882-
8191 or 882-0062. 
 
If you have any questions regarding your rights as a participant in this research and/or 
concerns about the study, or if you feel under any pressure to enroll or to continue to 
participate in this study, you may contact the University of Missouri Health Sciences 
Institutional Review Board (which is a group of people who review the research studies 
to protect participants’ rights) at (573) 882-3181 
 
A copy of this consent form will be given to you to keep.
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Signature 
I confirm that the purpose of the research, the study procedures, the possible risks and 
discomforts as well as potential benefits that I may experience have been explained to 
me.  Alternatives to my participation in the study also have been discussed.  I have read 
this consent form and my questions have been answered.  My signature below indicates 
my willingness to participate in this study. 
 
             
Subject/Patient*        Date 
 
             
Legal Guardian/Advocate/Witness (if required)**    Date 
 
             
Additional Signature (if required) (identify relationship to subject)*** Date 
 
*A minor’s signature on this line indicates his/her assent to participate in this study.  A 
minor’s signature is not required if he/she is under 7 years old.  Use the “Legal 
Guardian/Advocate/Witness” line for the parent’s signature, and you may use the 
"Additional Signature" line for the second parent’s signature, if required. 
 
**The presence and signature of an impartial witness is required during the entire 
informed consent discussion if the patient or patient’s legally authorized representative is 
unable to read.   
 
***The "Additional Signature" line may be used for the second parent’s signature, if 
required.  This line may also be used for any other signature which is required as per 
federal, state, local, sponsor and/or any other entity requirements. 
 
“If required” means that the signature line is signed only if it is required as per federal, 
state, local, sponsor and/or any other entity requirements. 
 
SIGNATURE OF STUDY REPRESENTATIVE 
I have explained the purpose of the research, the study procedures, identifying those that 
are investigational, the possible risks and discomforts as well as potential benefits and 
have answered questions regarding the study to the best of my ability. 
 
             
Study Representative****      Date 
****Study Representative is a person authorized to obtain consent.  Per the policies of 
the University of Missouri Health Care, for any 'significant risk/treatment' study, the 
Study Representative must be a physician who is either the Principal or Co-Investigator.  
If the study is deemed either 'significant risk/non-treatment' or 'minimal risk,' the Study 
Representative may be a non-physician study investigator.   
  
 
92
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     APPENDIX C 
 
                                      SUBJECT FORMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
93
University of Missouri-Columbia 
Exercise Physiology Lab 
Health History and Medical Questionnaire 
 
Name:_____________________Date:_________________ Age:_____________ 
Address:______________________________________ Sex:  Male      Female 
_____________________________Height:_______________ Weight:_________ 
Telephone: ____________________________________
 Email:___________________________________ 
Personal Physician’s Name:______________________ 
Blood Pressure:_____________/______________ 
Address & 
Telephone:____________________________________________________________ 
Health History: 
Have you ever had: High Blood Pressure  Y / N Low Blood Pressure  Y / N  
Heart Disease  Y / N 
Irregular Heart Beat  Y / N Diabetes Y / N    Heart Murmurs Y / N     Chest Pain Y / N 
Thyroid Disease Y / N    Lung Disease Y / N     Arthritis  Y / N   
High Blood Cholesterol  Y / N 
Has a parent or sibling had any heart disorders prior to age 55? Y / N 
Has a sudden death ever occurred in a parent or sibling?  Y / N 
Do you smoke?  Y / N If Yes, how much? __________ 
You are an/a African-American ___ Asian___ Caucasian___ Hispanic___ Native 
American___ Pacific Islander___ Other___ 
Have you ever taken medication for? Medication and Dosage  
 Date 
Y / N High Blood Pressure: ___________________________________________  
Y / N Low Blood Pressure: ___________________________________________  
Y / N Heart Disease: ________________________________________________  
Y / N Diabetes: ____________________________________________________  
Y / N Thyroid Disease: ______________________________________________  
Y / N Lung Disease: ________________________________________________  
Y / N Arthritis: ____________________________________________________   
Do you participate in a regular exercise program?  Y / N  
Times per week: ___________________________ 
For how many years?  _______________   
What activity? ___________________________________ 
If you are a woman, is there any chance you could be pregnant?  
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Medical Questionnaire: 
1. Have you ever been advised by a physician to avoid exercise?   Y / N  
2. Do you ever have shortness of breath during or after exercise?   Y / N 
3. Have you ever experienced fainting or dizzy spells?    Y / N 
4. Have you ever experienced pain or discomfort in the chest?   Y / N 
5. Have you ever experienced back, jaw or left arm pain or recurrent indigestion?  Y / N 
6. Have you ever experienced swollen ankles (excluding sprains)?  Y / N 
7. Have you recently experienced heart palpitations (rapid heart beat) at rest? Y / N 
8. Have you ever experienced claudication (pain in the calf, thigh, or buttocks with 
walking)? Y / N 
9. Is there any other health condition that might limit your participation in exercise 
programs (e.g., bone or joint disorders, pregnancy, etc.)?   Y / N  If Yes, please 
explain:__________________________________ 
10. Are you taking any medication not listed above? Y / N   
      If Yes, please list:__________________________ 
11. Have you had a medical exam in the last 12 month? Y / N  
      If Yes, please list date:___________________ 
 
Signature:___________________________________
 Date:___________________________________   
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University of Missouri-Columbia 
Exercise Physiology Lab 
 
Follow-up Medical History Questions 
 
8.  Have you had any surgeries?  Please list 
 
 
 
 
 
 
10.  Did you have any medical conditions for which you received treatment during the 
past year? 
 
 
 
 
 
Do you take any vitamins or dietary supplements?  Please list 
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University of Missouri-Columbia 
Exercise Physiology Lab 
 
Additional Medical Questionnaire  
(For Women only) 
 
     1.  Do you have a menstrual cycle?        Yes       No 
          If Yes, go to question #2 
          If No, go to question #5 
 
2. What is the frequency of your menstrual cycle? _____ times/year 
 
3. How many days does each cycle last? _____ days. 
 
4. When was your last menstrual period? 
 
5. Are you taking birth control pills?   Yes   No 
 
5a. If Yes, please record the brand name_____________________, 
      the amount_______________. 
 
6.  Are you on estrogen therapy?   Yes   No 
 
7. If Yes, please list the name (s), and frequency. 
                   Name                                  Frequency (i.e. 1 per day) 
 
 
________________________   __________________________________ 
________________________   __________________________________ 
________________________   __________________________________ 
________________________   __________________________________ 
________________________   __________________________________ 
________________________   __________________________________ 
 
Additional comments: 
 
 
 
 
 
  
 
97
University of Missouri-Columbia 
Exercise Physiology Lab 
Activity Questionnaire 
 
(Please circle appropriate response and elaborate when necessary) 
 
Name: _____________________________  Date: _______________  Weight: ______  
Gender: Male    Female   Age: ________ 
 
1. Do you usually engage in some form of planned regular or semi-regular exercise? 
Yes  No (If no, please go to the last question) 
 
2. Are you currently exercising? 
Yes  No (If Yes, please answer Question #3 in detail) 
 
3. Please complete the following table.  Please give your best estimate! 
Mode of exercise (jog, 
bike, swim, etc.) 
Days per 
week 
Duration 
(minutes) 
Pace 
(mph) 
Intensity (mild/ 
mod/vigor) 
History 
(# of months) 
________________ _______ ________ _______ ____________ __________ 
________________ _______ ________ _______ ____________ __________ 
________________ _______ ________ _______ ____________ __________ 
________________ _______ ________ _______ ____________ __________ 
________________ _______ ________ _______ ____________ __________ 
 
4. Are you presently, or have you recently trained for a competitive event? 
Yes  No      (If yes, what event_______ and duration of training______) 
 
5. Do you have any comments about your exercise program that you feel we should 
know about?   
Yes  No  (If yes, Please explain in space provided below) 
_____________________________________________________________________
_____________________________________________________________________
____________________________________________________________________ 
  
6. Does your occupation or daily routine involve a considerable amount of activity?  For 
example, walking, stair climbing, lifting, etc.? 
Yes  No (If yes, Please explain in the space provided below) 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
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Dietary record 
  Date:  
Day of 
week:  
Time 
of 
Day Food/Drink Brand  
Amount   
(tsp, cup, 
oz) Condiments 
Locat
ion/P
lace 
BREAKFAST 
                
          
          
     
         
MORNING SNACK 
            
            
            
LUNCH 
                                
            
            
            
            
            
      
      
Time 
of 
Day Food/Drink Brand  
Amount   
(tsp, cup, 
oz) Condiments 
Locat
ion/P
lace 
AFTERNOON SNACK 
            
            
                    
DINNER 
                    
            
            
            
            
            
            
                  
EVENING SNACK 
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Exercise training form 
 
   Max HR______                                                                                       SUBJECT #______ 
   Target HR (75% HRmax)______                                                           week #______week date______ -______  
                  group ______ 
                                           
                                               GET FIT NOW IN-LAB TRAINING LOG 
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 min  2 min  3 min   min 1 min 2 min 3 min 4 min 5 
WARM-
UP HR 
   COOL 
DOWN 
HR 
     
TIME 
(after 
warmup) 
5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 
HR          
SPEED          
  1 min  2 min  3 min   min 1 min 2 min 3 min 4 min 5 
WARM-
UP HR 
   COOL 
DOWN 
HR 
     
TIME 
(after 
warmup) 
5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 
HR          
SPEED          
1 min  2 min  3 min   min 1 min 2 min 3 min 4 min 5 
WARM-
UP HR 
   COOL 
DOWN 
HR 
     
TIME 
(after 
warmup) 
5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 
HR          
SPEED          
1 min  2 min  3 min   min 1 min 2 min 3 min 4 min 5 
WARM-
UP HR 
   COOL 
DOWN 
HR 
     
TIME 
(after 
warmup) 
5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 
HR          
SPEED          
 1 min  2 min  3 min   min 1 min 2 min 3 min 4 min 5  
WARM-
UP HR 
   COOL 
DOWN 
HR 
     
TIME 
(after 
warmup) 
5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 
HR          
SPEED          
  Day_____ 
  Date_____ 
  Session____ 
  Initials_____ 
  Body wt.____ 
  Rest HR_____ 
 
   Day_____ 
   Date_____ 
   Session_____ 
   Initials______ 
   Body wt.____ 
   Rest HR_____ 
 
   Day_____ 
   Date_____ 
   Session_____ 
   Initials______ 
   Body wt.____ 
   Rest HR_____ 
 
   Day_____ 
   Date_____ 
   Session_____ 
   Initials______ 
   Body wt._____ 
   Rest HR_____ 
   Day_____ 
   Date_____ 
   Session_____ 
   Initials_____ 
   Body wt.____ 
   Rest HR____ 
 
 
           ****COOL DOWN TO 110 BPM***  
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                                             APPENDIX D 
 
                             STATISTICAL RESULTS 
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Two-way repeated measures ANOVA 
Statistical results: TG AUCT in PPL (mg/dl* 8hr) 
Source of Variation df F P-value 
Treatment 1 0.902 0.353 
Time 1 5.596 0.028 
Treatment x Time 1 1.807 0.194 
 
Statistical results: TG AUCI in PPL (mg/dl* 8hr) 
Source of Variation df F P-value 
Treatment 1 0.314 0.581 
Time 1 0.208 0.653 
Treatment x Time 1 2.119 0.161 
 
Statistical results: TG PeakT in PPL (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.303 0.588 
Time 1 2.23 0.151 
Treatment x Time 1 3.101 0.094 
 
Statistical results: TG PeakI in PPL (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.00007 0.993 
Time 1 0.046 0.832 
Treatment x Time 1 3.461 0.078 
 
Statistical results: TG PPL 0h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 1.305 0.267 
Time 1 27.642 <0.001 
Treatment x Time 1 0.0614 0.807 
 
Statistical results: TG PPL 2h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.134 0.718 
Time 1 4.311 0.051 
Treatment x Time 1 1.89 0.184 
 
Statistical results: TG PPL 4h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 1.032 0.322 
Time 1 5.629 0.028 
Treatment x Time 1 2.2 0.153 
 
Statistical results: TG PPL 6h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 1.183 0.29 
Time 1 1.593 0.221 
Treatment x Time 1 1.236 0.28 
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Statistical results: TG PPL 8h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 1.477 0.238 
Time 1 7.686 0.012 
Treatment x Time 1 0.102 0.752 
 
Statistical results: TG AUCT in Ex-PPL (mg/dl* 8hr) 
Source of Variation df F P-value 
Treatment 1 0.271 0.608 
Time 1 12.681 0.002 
Treatment x Time 1 0.151 0.702 
 
Statistical results: TG AUCI in Ex-PPL (mg/dl* 8hr) 
Source of Variation df F P-value 
Treatment 1 0.0104 0.92 
Time 1 1.625 0.217 
Treatment x Time 1 0.0296 0.865 
 
Statistical results: TG PeakT in Ex-PPL (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.005 0.944 
Time 1 9.097 0.007 
Treatment x Time 1 0.594 0.45 
 
Statistical results: TG PeakI in Ex-PPL (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.642 0.433 
Time 1 1.885 0.185 
Treatment x Time 1 0.333 0.57 
 
Statistical results: TG Ex-PPL 0h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.588 0.452 
Time 1 21.725 <0.001 
Treatment x Time 1 0.716 0.407 
 
Statistical results: TG Ex-PPL 2h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.0059 0.94 
Time 1 7.386 0.013 
Treatment x Time 1 0.896 0.355 
 
Statistical results: TG Ex-PPL 4h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.0593 0.81 
Time 1 10.321 0.004 
Treatment x Time 1 0.506 0.485 
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Statistical results: TG Ex-PPL 6h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.473 0.5 
Time 1 11.589 0.003 
Treatment x Time 1 0.551 0.467 
 
Statistical results: TG Ex-PPL 8h (mg/dl) 
Source of Variation df F P-value 
Treatment 1 2.096 0.163 
Time 1 8.001 0.01 
Treatment x Time 1 0.0485 0.828 
 
Statistical results: HDL-C in fasting samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.475 0.499 
Time 1 6.725 0.017 
Treatment x Time 1 1.246 0.278 
 
Statistical results: HDL3-C in fasting samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.153 0.7 
Time 1 15.062 <0.001 
Treatment x Time 1 0.783 0.387 
 
Statistical results: HDL2-C in fasting samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 1.124 0.302 
Time 1 31.793 <0.001 
Treatment x Time 1 3.564 0.074 
 
Statistical results: HDL-C in exercise samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.0824 0.777 
Time 1 1.803 0.194 
Treatment x Time 1 0.464 0.503 
 
Statistical results: HDL3-C in exercise samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.079 0.782 
Time 1 9.466 0.006 
Treatment x Time 1 0.813 0.378 
 
Statistical results: HDL2-C in exercise samples (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.344 0.564 
Time 1 27.695 <0.001 
Treatment x Time 1 3.45 0.078 
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Statistical results: LDL (mg/dl) 
Source of Variation df F P-value 
Treatment 1 0.626 0.438 
Time 1 0.229 0.637 
Treatment x Time 1 1.577 0.224 
 
Statistical results: CRP in fasting samples (mg/L) 
Source of Variation df F P-value 
Treatment 1 0.435 0.517 
Time 1 0.0134 0.909 
Treatment x Time 1 1.998 0.173 
 
Statistical results: CRP in exercise samples (mg/L) 
Source of Variation df F P-value 
Treatment 1 0.757 0.395 
Time 1 2.685 0.117 
Treatment x Time 1 2.422 0.135 
 
Statistical results: IL-6 (pg/ml) 
Source of Variation df F P-value 
Treatment 1 0.0173 0.897 
Time 1 2.246 0.158 
Treatment x Time 1 0.998 0.336 
 
Statistical results: sICAM-1 (ng/ml) 
Source of Variation df F P-value 
Treatment 1 0.69 0.416 
Time 1 2.414 0.136 
Treatment x Time 1 0.457 0.507 
 
One-way ANOVA 
 
Characteristics of subjects between groups before treatment 
  df F P value 
Age (yr) 1 0.071 0.793 
Body weight (kg) 1 0.593 0.45 
BMI (kg/m2) 1 0.195 0.664 
Waist/hip ratio 1 0.018 0.894 
% fat 1 0.167 0.687 
VO2max (L/min) 1 0.0497 0.826 
max HR (beat/min) 1 0.821 0.376 
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One-way repeated measures ANOVA 
 
Characteristics of subjects within FO group pre vs. post treatment 
  df F P value 
BMI (kg/m2) 1 0.144 0.713 
Waist/hip ratio 1 4.125 0.073 
% fat 1 3.78 0.084 
VO2max (L/min) 1 0.546 0.481 
max HR (beat/min) 1 2.333 0.161 
 
Characteristics of subjects within FO+ExTr group pre vs. post treatment 
  df F P value 
BMI (kg/m2) 1 4.678 0.053 
Waist/hip ratio 1 0.262 0.619 
% fat 1 33.667 <0.001 
VO2max (L/min) 1 17.667 0.001 
max HR (beat/min) 1 0.353 0.565 
 
FO group PPL TG pre vs. post 
  df F P value 
AUCT (mg/dl*8hr) 1 4.716 0.058 
AUCI (mg/dl*8hr) 1 1.247 0.293 
PeakT (mg/dl) 1 4.215 0.07 
PeakI (mg/dl) 1 1.855 0.206 
0h (mg/dl) 1 18.042 0.002 
2h (mg/dl) 1 3.558 0.092 
4h (mg/dl) 1 9.836 0.012 
6h (mg/dl) 1 1.867 0.205 
8h (mg/dl) 1 2.813 0.128 
 
FO+ExTr group PPL TG pre vs. post 
  df F P value 
AUCT (mg/dl*8hr) 1 1.212 0.295 
AUCI (mg/dl*8hr) 1 0.542 0.477 
PeakT (mg/dl) 1 0.0059 0.94 
PeakI (mg/dl) 1 1.372 0.266 
0h (mg/dl) 1 14.737 0.003 
2h  1 0.746 0.406 
4h (mg/dl) 1 0.556 0.472 
6h (mg/dl) 1 0.746 0.79 
8h (mg/dl) 1 8.068 0.016 
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FO group Ex-PPL TG pre vs. post 
  df F P value 
AUCT (mg/dl*8hr) 1 3.992 0.077 
AUCI (mg/dl*8hr) 1 1.643 0.232 
PeakT (mg/dl) 1 1.581 0.24 
PeakI (mg/dl) 1 0.229 0.644 
0h (mg/dl) 1 5.93 0.038 
2h  1 1.092 0.323 
4h (mg/dl) 1 4.926 0.054 
6h (mg/dl) 1 5.121 0.05 
8h (mg/dl) 1 4.503 0.063 
 
FO+ExTr group Ex-PPL TG pre vs. post 
  df F P value 
AUCT (mg/dl*8hr) 1 9.831 0.009 
AUCI (mg/dl*8hr) 1 0.499 0.495 
PeakT (mg/dl) 1 12.674 0.004 
PeakI (mg/dl) 1 2.684 0.13 
0h (mg/dl) 1 18.577 0.001 
2h  1 9.966 0.009 
4h (mg/dl) 1 5.327 0.041 
6h (mg/dl) 1 7.277 0.021 
8h (mg/dl) 1 4.085 0.068 
 
FO group HDL-C and subfractions in fasting sample pre vs. post 
  df F P value 
HDL-C (mg/dl) 1 1.275 0.288 
HDL3-C (mg/dl) 1 4.26 0.069 
HDL2-C (mg/dl) 1 6.692 0.029 
 
 
FO+ExTr group HDL-C and subfractions in fasting sample pre vs. post 
  df F P value 
HDL-C (mg/dl) 1 6.432 0.028 
HDL3-C (mg/dl) 1 12.152 0.005 
HDL2-C (mg/dl) 1 30.25 0.001 
 
FO group CRP fasting vs. exercise (mg/L) 
  df F P value 
pre 1 0.269 0.617 
post 1 1.505 0.245 
 
FO+ExTr group CRP fasting vs. exercise (mg/L) 
  df F P value 
pre 1 0.045 0.836 
post 1 0.729 0.415 
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PPL TG values and parameters 
 
Sub# Trial AUCT AUCI PeakT PeakI 0 hr 2hr 4 hr 6 hr 8hr
1 pre-P 1344.8 108.8 205.1 50.6 154.5 205.1 175 153.4 123.3
1 pre-E 1447.6 255.6 225 76.0 149.0 201.7 164.7 225 115.8
1 post-P 1807.9 534.3 279.8 120.6 159.2 245.9 230.5 279.8 136.3
1 post-E 1233.6 370.4 204.8 96.9 107.9 204.8 176.4 134.9 93.5
4 pre-P 641.4 111.0 92.6 26.3 66.3 91.5 92.6 74.4 58.1
4 pre-E 822.8 8.4 118.7 16.9 101.8 118.7 102.6 90.5 97.4
4 post-P 831.2 271.2 140.4 70.4 70.0 103 93.7 140.4 87
4 post-E 1277.1 294.7 206.9 84.1 122.8 206.9 166.6 139 129.3
5 pre-P 901.5 92.7 159.5 58.4 101.1 159.5 115.2 79.2 92.6
5 pre-E 1301.5 444.7 211.9 104.8 107.1 157.6 211.9 166.9 121.6
5 post-P 906.2 237.4 136.4 52.8 83.6 111.5 106.7 136.4 113.4
5 post-E 823.0 210.2 129.4 52.8 76.6 115.6 87.7 129.4 81
6 pre-P 1494.1 496.5 270.5 145.8 124.7 270.5 213.7 148.3 104.4
6 pre-E 1137.9 561.9 195.9 123.9 72.0 195.9 181.5 120.7 69.7
6 pre-P 946.8 129.2 175.6 73.4 102.2 175.6 126.2 77.9 85.2
6 pre-E 1201.6 620.0 231.4 158.7 72.7 231.4 183.4 104.1 91.1
7 pre-P 1989.2 808.4 302.1 154.5 147.6 232.8 302.1 268.3 235.2
7 pre-E 2203.3 445.7 335.9 116.2 219.7 335.9 295.9 239.3 241.4
7 post-P 1398.4 278.4 195.2 55.2 140.0 195.2 185.9 155.5 185.2
7 post-E 1581.6 337.6 220 64.5 155.5 213.4 220 196.2 166.9
8 pre-P 1110.6 419.4 182.8 96.4 86.4 135.3 182.8 146.9 94.2
8 pre-E 1308.5 312.5 179.1 54.6 124.5 171.6 179.1 176.8 129
8 post-P 761.8 244.2 120 55.3 64.7 104.3 120 88.2 72.1
8 post-E 816.2 74.6 127.9 35.2 92.7 127.9 101.7 98.7 66.9
9 pre-P 1607.7 602.1 235.3 109.6 125.7 188.4 241.7 235.3 151.2
9 pre-E 1414.3 540.7 219.4 110.2 109.2 191.9 219.4 194.9 92.7
9 post-P 1069.6 439.2 164.4 85.6 78.8 138.5 153.5 164.4 78
9 post-E 1138.6 350.6 176.6 78.1 98.5 165.2 176.6 127.5 101.5
11 pre-P 996.4 199.6 138.7 39.1 99.6 138.7 136.6 136.9 72.4
11 pre-E 789.2 100.4 132.5 46.4 86.1 132.5 94.2 85.7 78.3
11 pre-P 792.3 258.7 116.8 50.1 66.7 116.8 109.3 97.8 77.8
11 pre-E 782.7 203.5 106.5 34.1 72.4 106.1 106.5 103.2 78.7
12 pre-P 2652.5 1297.3 418.1 248.7 169.4 362.4 339.1 418.1 243.9
12 pre-E 2243.9 694.3 346.1 152.4 193.7 282.3 346.1 304.8 183.8
12 post-P 1286.7 209.1 187.5 52.8 134.7 187.5 185.6 154.2 97.4
12 post-E 1578.8 536.4 252.8 122.5 130.3 209.6 252.8 202.6 118.5
13 pre-P 918.5 92.1 138.4 35.1 103.3 138.4 133.6 85.6 100
13 pre-E 1128.7 208.7 179.4 64.4 115.0 179.4 145 120.8 123.3
13 post-P 1024.0 250.4 154.2 57.5 96.7 154.2 147.6 105.2 113.3
13 post-E 1124.6 222.2 215.9 103.1 112.8 215.9 158 87.5 89
14 pre-P 1324.5 338.9 183.9 60.7 123.2 169.7 162 177 183.9
14 pre-E 1739.7 432.5 253 89.6 163.4 225.6 193.1 253 232.9
14 post-P 1276.9 335.3 178.8 61.1 117.7 178.1 163.1 178.8 119.2
14 post-E 1231.1 350.3 179.9 69.8 110.1 157.2 179.9 154.3 138.2
16 pre-P 1221.6 194.4 181.5 53.1 128.4 153.5 181.5 153.1 117
16 pre-E 1228.1 47.3 193.4 45.8 147.6 156.1 193.4 135.4 110.7
16 pre-P 1296.1 460.9 200 95.6 104.4 200 187.5 150.6 115.5
16 pre-E 1007.9 275.9 147.6 56.1 91.5 146.9 147.6 120.7 86  
 
Note: pre-P, PPL pre testing; pre-E, Ex-PPL pre testing; post-P, PPL post testing; post-E, 
Ex-PPL post testing. 
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PPL TG values and parameters (Cont.) 
 
Sub# Trial AUCT AUCI PeakT PeakI 0 hr 2hr 4 hr 6 hr 8hr
18 pre-P 1374.3 219.9 196.7 52.4 144.3 196.7 195.6 160.5 124.4
18 pre-E 1049.5 284.7 148 52.4 95.6 147.6 148 109.6 143.5
18 post-P 1089.7 422.5 186 102.6 83.4 186 152.4 124 81.5
18 post-E 1037.1 308.3 150.6 59.5 91.1 129.2 150.6 110 166.4
19 pre-P 1155.4 77.0 159.3 24.5 134.8 149.3 159.3 143.4 116.6
19 pre-E 1372.8 73.6 219 56.6 162.4 219 176.2 153.1 113.8
19 post-P 1166.7 225.9 204.8 87.2 117.6 204.8 134.8 131 107.9
19 post-E 1277.1 294.7 206.9 84.1 122.8 206.9 166.6 139 129.3
21 pre-P 1219.5 149.1 176.6 42.8 133.8 176.6 165.9 145.2 110.3
21 pre-E 1149.5 117.5 164.5 35.5 129.0 161.4 164.5 128.3 112.1
21 post-P 1049.8 161.8 159.7 48.7 111.0 159.7 140.7 117.6 102.8
21 post-E 1153.9 155.5 166.2 41.4 124.8 164.5 166.2 132.8 102.1
24 pre-P 1071.1 430.3 177 96.9 80.1 177 159.8 104.6 108.2
24 pre-E 1250.4 425.6 204 100.9 103.1 184.3 204 146.6 77.5
24 pre-P 984.1 489.7 184.3 122.5 61.8 184.3 134.6 109.7 65.1
24 pre-E 747.3 208.9 118.1 50.8 67.3 118.1 91.8 101.6 57
25 pre-P 1678.2 444.6 278.4 124.2 154.2 157.5 234.4 278.4 183.4
25 pre-E 875.9 298.3 124.5 52.3 72.2 116.4 124.5 121.9 78.1
25 post-P 1262.3 475.9 186.7 88.4 98.3 181.5 148.2 186.7 131.2
25 post-E 801.5 276.7 126.3 60.7 65.6 99.1 103.9 126.3 77.3
27 pre-P 3223.0 953.4 463.6 179.9 283.7 400.4 463.6 455.3 300.7
27 pre-E 3345.6 1216.0 468 201.8 266.2 415.3 463.9 468 385
27 post-P 3664.3 1493.1 622.4 351.0 271.4 374.2 622.4 556.3 287.1
27 post-E 2265.8 435.4 327.5 98.7 228.8 285.2 327.5 267.3 277
28 pre-P 1050.2 246.2 156.6 56.1 100.5 139.2 156.6 126.6 104.9
28 pre-E 813.1 197.1 114.1 37.1 77.0 114.1 111.2 102.6 80.3
28 post-P 752.3 147.5 116.8 41.2 75.6 85.4 116.8 96.2 79.9
28 post-E 867.2 136.0 120.1 28.7 91.4 120.1 118.2 103.7 91.8
29 pre-P 1504.3 375.5 246.8 105.7 141.1 246.8 203.7 162 138.2
29 pre-E 1996.5 370.1 335.6 132.3 203.3 335.6 277.1 211.7 144.4
29 pre-P 1077.8 83.4 185.4 61.1 124.3 185.4 124.3 117.7 98.7
29 pre-E 1251.4 131.4 200 60.0 140.0 200 150.6 152.8 104.6
34 pre-P 849.0 168.2 119.3 34.2 85.1 119.3 117.8 99.3 91.1
34 pre-E 1136.2 237.8 163.6 51.3 112.3 163.6 139.4 155.8 106.3
34 post-P 819.0 188.6 127.9 49.1 78.8 89.2 101.9 127.9 102.2
34 post-E 546.5 97.7 77 20.9 56.1 62.1 71.7 72.9 77
37 pre-P 1131.2 257.2 153.1 43.9 109.2 152.7 153.1 137.0 136.3
37 pre-E 949.3 100.0 142.8 36.6 106.2 142.8 109.9 115.4 106.8
37 post-P 1122.6 240.4 152.7 42.4 110.3 141.8 145.5 152.7 132.2
37 post-E 873.6 120.2 120.9 26.7 94.2 117.1 105.5 120.9 92.5  
 
Note: pre-P, PPL pre testing; pre-E, Ex-PPL pre testing; post-P, PPL post testing; post-E, 
Ex-PPL post testing. 
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Characteristics of subjects before treatment 
Subject Weight (kg) BMI (kg*m2) W:H % fat VO2max (l/min) max HR 
1 81.2 24.9 0.8 16.87 3.28 183
7 84.9 26.2 0.898 21.99 3.34 191
9 95.1 30.52 0.97 24.4 2.98 155
11 66.4 24.8 0.75 33.4 2.43 187
14 78.1 28.86 0.787 38.16 2.87 210
16 65.3 24.13 0.73 32.24 2.11 179
18 80.1 25.42 0.76 20.57 2.9 179
19 71.7 23.95 0.68 33.2 2.54 197
27 88.6 27.16 0.907 15.75 3.41 204
28 77.3 28.91 0.747 34.38 1.49 165
34 68.8 26.22 0.773 25.9 2.6 177
37 78 26.06 0.864 17.49 3.3 189
4 73 29.9 0.74 33.2 2.24 206
5 84 29.93 0.83 41.6 2.7 192
6 83.5 25.07 0.814 17.12 4.23 196
8 78.1 26.7 0.86 14.07 2.86 204
12 94.9 26.99 0.901 17.81 3.78 171
13 84.3 29.17 0.767 43.2 2.23 194
21 65.5 23.77 0.725 29.12 2.05 188
24 67.5 22.8 0.81 9.26 3.53 201
25 79.9 27.3 0.732 32.59 n/a 175
29 72.3 26.88 0.833 41.92 1.93 175  
Note: W:H, waist/hip ratio; max HR, maximal heart rate (beat/min). 
  
Characteristics of subjects after treatment 
Subject Weight (kg) BMI (kg*m2) w:h % fat VO2max(l/min) max HR 
1 81.61 25.04 0.854 14.69 3.77 175
7 86 26.54 0.896 20.48 3.36 181
9 94.8 30.43 0.94 22.43 3.15 150
11 66.9 25.02 0.7448 31.34 2.54 191
14 78.75 29.1 0.792 34.6 2.85 201
16 65.45 24.18 0.747 28.07 2.43 188
18 82.1 26.05 0.788 17.49 3.01 172
19 73.72 24.63 0.675 31.12 2.58 198
27 88.45 27.14 0.871 14.58 3.82 200
28 78.1 29.21 0.731 31.57 1.8 167
34 68.4 26.06 0.785 24.8 2.8 182
37 77.4 25.86 0.887 18.05 3.46 197
4 75.05 30.83 0.743 38.87 2.15 199
5 82.6 29.4 0.842 37.26 2.66 188
6 82.4 24.74 0.806 15.56 4.27 198
8 78.51 26.85 0.866 10.97 3 199
12 91.8 26.12 0.926 16.36 3.74 171
13 83.1 28.75 0.761 39.58 2.08 189
21 66.2 24.02 0.741 27.06 2.14 196
24 70.52 23.83 0.867 7.09 3.85 194
25 82.1 28.07 0.765 31.4 n/a 175
29 71.8 26.69 0.827 38.54 1.97 170  
Note: W:H, waist/hip ratio; max HR, maximal heart rate (beat/min). 
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HDL-C and subfractions before treatment in fasting samples(mg/dl) 
Sub Time HDL-C HDL3-C HDL2-C
27 pre 37.1 24.8 12.3
28 pre 41.4 25.3 16.1
34 pre 61.8 36.2 25.6
18 pre 47.8 32.1 15.7
19 pre 98.9 47.5 51.5
14 pre 53.9 35.1 18.8
16 pre 58.2 32 26.2
7 pre 40.2 29 11.2
9 pre 42.6 37.8 4.8
1 pre 44.1 33.9 10.2
11 pre 46.3 28.2 18.1
37 pre 72.5 39.2 33.3
25 pre 81.5 42.4 39.1
29 pre 49.8 34.1 15.8
21 pre 45.8 33.1 12.7
13 pre 48.6 34.8 13.8
8 pre 46.2 33.8 12.4
4 pre 44.5 30.3 14.3
6 pre 50.5 38.5 12
5 pre 44.6 29.1 15.5
12 pre 50.4 30.9 19.5
24 pre 40.7 30 10.6  
 
HDL-C and subfractions after treatment in fasting samples (mg/dl) 
Sub Time HDL-C HDL3-C HDL2-C
27 post 37.1 24.5 12.7
28 post 47.2 24.9 22.3
34 post 61.1 27.9 33.2
18 post 55 31.2 23.8
19 post 103.2 41.2 62
14 post 65.9 33.5 32.5
16 post 65.3 31.9 33.4
7 post 40.1 25.1 15
9 post 45.1 33.2 11.9
1 post 39.2 29.2 10.1
11 post 56.4 28.6 27.7
37 post 72.9 36.3 36.5
25 post 86.2 36.6 49.6
29 post 48.3 30.3 18
21 post 42.1 30.2 11.9
13 post 49.1 34.7 14.5
8 post 45.6 29.9 15.8
4 post 44.9 27.9 17
6 post 55 36.7 18.3
5 post 51.4 29 22.4
12 post 46.7 30.2 16.5
24 post 47.8 33.9 13.8  
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HDL-C and subfractions before treatment in exercise samples (mg/dl) 
Sub # Time HDL-C HDL3-C HDL2-C
27 pre 33.3 27.6 5.7
28 pre 43.1 30.7 12.4
34 pre 62.9 43.8 19.1
18 pre 51.3 40.7 10.5
19 pre 94.8 56.8 38
14 pre 50.7 38.2 12.5
16 pre 58.5 38.9 19.6
7 pre 35.7 28.4 7.3
9 pre 44.4 38.5 5.9
1 pre 44 37.9 6
11 pre 45.9 37.6 8.2
37 pre 67.3 43.5 23.7
25 pre 93.4 55.1 38.3
29 pre 49 38.1 10.9
21 pre 42.1 35.9 6.2
13 pre 50.2 42.4 7.8
8 pre 41 31.7 9.3
4 pre 44 33.5 10.5
6 pre 53.6 39.6 14
5 pre 48.4 35.7 12.7
12 pre 45.2 35.5 9.7
24 pre 46.3 36.3 9.9  
 
HDL-C and subfractions after treatment in exercise samples (mg/dl) 
Sub # Time HDL-C HDL3-C HDL2-C
27 post 35 29 6
28 post 44.5 29.3 15.2
34 post 65.6 31.5 34.1
18 post 47.7 34.7 13
19 post 98.9 48.5 50.5
14 post 61.5 44.5 17
16 post 58.3 32.7 25.6
7 post 37.8 25.1 12.7
9 post 43.6 35.6 8
1 post 42.2 34.7 7.5
11 post 52.9 33.2 19.7
37 post 65.2 36.6 28.6
25 post 88.5 44.5 44
29 post 44.8 33.3 11.5
21 post 49.7 37.5 12.2
13 post 46.7 36.6 10.2
8 post 46.6 36.4 10.1
4 post 46.6 35.5 11.2
6 post 54.4 39.3 15.1
5 post 48.1 31.7 16.4
12 post 44.9 32.8 12.1
24 post 48.7 34.7 14  
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CRP values in fasting samples 
Sub # CRP pre (mg/l) CRP post (mg/l) 
1 1.7 0.5 
4 2.3 3.2 
5 0.8 5.5 
6 1.4 2.3 
7 0.9 1.2 
8 2.8 1.2 
9 4.2 6.2 
11 2.4 1.1 
12 1.5 9.2 
13 9.5 9.2 
14 1.0 0.8 
16 0.8 1.4 
18 2.7 2.6 
19 28.8 17.6 
21 9.1 10.3 
24 0.5 1.0 
25 0.2 1.6 
27 1.7 0.8 
28 3.3 3.4 
29 18.2 13.7 
34 0.2 0.4 
37 0.4 1.0 
 
CRP values in exercise samples 
Sub # CRP pre (mg/L) CRP post (mg/L) 
1 0.2 0.1 
4 1.2 2.0 
5 1.7 7.9 
6 1.4 2.1 
7 0.9 0.7 
8 1.2 2.5 
9 3.5 4.7 
11 1.0 0.8 
12 1.6 0.5 
13 6.0 8.5 
14 0.2 5.2 
16 1.0 3.9 
18 3.2 3.3 
19 20.3 15.5 
21 12.7 13.6 
24 0.4 0.5 
25 1.6 1.0 
27 1.8 1.1 
28 4.4 2.6 
29 9.6 27.9 
34 0.1 0.1 
37 0.8 0.3 
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IL-6 values in Ex-PPL 2h samples 
Subject IL-6 pre (pg/ml) IL-6 post (pg/ml) 
1 5 4.8 
4 2.7 NA 
5 3.2 2.6 
6 2.5 2.7 
7 21.6 20.2 
8 2.7 3 
9 NA 2.7 
11 2.5 2.7 
12 2.5 2.8 
13 2.8 2.9 
14 NA 2.5 
16 2.4 2.5 
18 NA NA 
19 2.5 2.5 
21 2.3 2.7 
24 3.9 4.3 
25 2.2 2.4 
27 2.5 2.6 
28 NA 2.2 
29 2.4 2.6 
34 NA 2.6 
37 2.7 2.7 
Note: NA undetectable values. 
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sICAM-1 values 
Subject 
sICAM-1 pre 
(ng/ml) 
sICAM-1 post 
(ng/ml) 
1 104.7 94.2 
4 83.7 84.4 
5 94.8 85.8 
6 90.3 83.2 
7 68.6 66.0 
8 74.0 53.5 
9 58.9 64.2 
11 68.2 59.8 
12 80.9 80.6 
13 48.2 48.0 
14 61.9 66.9 
16 23.5 19.7 
18 114.8 99.0 
19 32.2 16.0 
21 33.2 35.4 
24 30.9 24.0 
25 36.2 40.3 
27 10.3 25.6 
28 19.2 23.1 
29 36.4 30.4 
34 12.1 7.5 
37 11.7 23.8 
 
 
